

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

The impact of dexmedetomidine on mortality in critically ill patients with acute kidney injury: A retrospective propensity score matching analysis

Manuscript ID	bmjopen-2023-073675
	biljopen 2025 075075
Article Type:	Original research
Date Submitted by the Author:	14-Mar-2023
	Wang, Wenting; Peking Union Medical College Jin, Yu; Peking Union Medical College Zhang, Peiyao; Peking Union Medical College Gao, Peng; Peking Union Medical College Wang, He; Peking Union Medical College, Department of Cardiopulmonary Bypass Liu, Jinping; Peking Union Medical College, Department of Cardiopulmonary Bypass
	INTENSIVE & CRITICAL CARE, Acute renal failure < NEPHROLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



The impact of dexmedetomidine on mortality in critically ill patients with acute kidney injury: A retrospective propensity score matching analysis

Authors: Wenting Wang¹, Yu Jin¹, Peiyao Zhang¹, Peng Gao¹, He Wang¹, Jinping Liu¹*

Institutions: ¹Department of Cardiopulmonary Bypass, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Corresponding Author: Jinping Liu; Fuwai hospital, No.167, North Lishi Road, Xicheng District, 100037, Beijing, China; E-mail: liujinping@fuwai.com; TEL: 010-88396257, FAX: 010-88396257.

Conflicts of interest statement: The authors have declared no conflicts of interest for this article.

Funding: This study was supported by The National Natural Science Fundation of China (grant number: 81960669) and The National High Level Hospital Clinical Research Funding (grant number: 2022-GSP-GG-22)

Author Contributions:

WW and JL designed the study. YJ and PZ conducted data collection. PG and HW conducted data analysis. WW wrote the manuscript. WW and JL analyzed and interpreted the result. All authors reviewed this manuscript.

Abstract:

Objectives This study sought to estimate the effect of dexmedetomidine (DEX) administration on acute kidney injury (AKI)-associated mortality in critically ill patients.

Design A retrospective cohort study.

Setting The study sourced its data from the Multiparameter Intelligent Monitoring in Intensive Care Database IV (MIMIC-IV), a comprehensive database of ICU patients.Participants A total of 15754 critically ill patients with AKI were enrolled from the

MIMIC-IV database.

Primary and secondary outcome In-hospital mortality and 180-day mortality.

Results 15754 critically ill AKI patients were included in our analysis. We found that DEX use decreased in-hospital mortality risk by 38% (HR: 0.62, 95% CI: 0.55-0.70). A significant decrease in in-hospital mortality was observed following treatment with DEX among critically ill patients with AKI stage 1 (15.6% vs. 10.7%, p< 0.001), stage 2 (18.5% vs. 14.7%, p = 0.017) but not stage 3 (27.6% vs. 26.6%, p = 0.848). Moreover, the 180-day mortality was reduced at AKI stage 1 (24.7% vs. 18.2%) and stage 2 (28.3% vs. 24.0%) but not stage 3 (39.1% vs. 38.3%).

Conclusions Our retrospective cohort study suggests that DEX significantly correlates with decreased risk-adjusted in-hospital and 180-day mortality in critically ill AKI patients. Nonetheless, future randomized controlled trials (RCTs) are warranted to validate our findings.

Keywords: Dexmedetomidine, AKI, Mortality, MIMIC-IV, Propensity score matching

Strengths and limitations of this study

• This study included 15754 patients, which is a very large sample size for a clinical study of critically ill patients with AKI.

- Additional confounding factors were adjusted and increased the reliability of our results and conducted a subgroup analysis of the association between DEX use and in-hospital mortality.
- This was a retrospective design and some data may be missing which slightly offsets the results, and we expect to further RCTs in the future.
- The conclusions are qualitative, not quantitative.

Introduction

Over the past few decades, the prevalence of acute kidney injury (AKI) has significantly increased and has gradually become a global health concern.¹ AKI is a common comorbidity among severely ill patients that require intensive care. Indeed, more than half of patients experience AKI during their stay in the intensive care unit (ICU).² AKI is related to adverse outcomes, increases CKD occurrence and kidney replacement therapy, and raises the risk of short- and long-term deaths,³ causing huge social and economic burdens to patients and society. However, further research is warranted to optimize the management of AKI.⁴

In the context of critical care, effective sedation is of utmost importance for managing agitation and anxiety in patients.⁵ The primary objective of sedation in the ICU is to achieve a state of calmness and cooperation in the patient, allowing for the easy awakening and clear communication of needs, particularly concerning pain management.⁶ There is evidence to suggest that maintaining light sedation in patients in the ICU can lead to better outcomes. Current guidelines recommend dexmedetomidine (DEX) for sedation in an intensive care setting.⁷ DEX is widely used in ICU as a highly selective alpha-2 agonist.⁸ An increasing body of evidence suggests that DEX can inhibit the production of excess inflammation cytokine and protect renal function, which may positively impact the prognosis of AKI.⁹⁻¹¹ However, the renoprotective effects of DEX in critically ill patients have not been explore, the current literature consists mainly of basic-level studies or small sample population cohorts,

BMJ Open

with a paucity of large-scale research. Hence, the present study aims to investigate DEX's effect on AKI-related mortality in critically ill patients.

Methods

Data sources

The study sourced its data from the Multiparameter Intelligent Monitoring in Intensive Care Database IV (MIMIC-IV), a comprehensive database of ICU patients.¹² We collected data on AKI patients from the MIMIC-IV database treated with or without DEX. This database contains a publicly available and real-world clinical database of patients at the Beth Israel Deaconess Medical Center from 2008 to 2019. Informed consent of patients was not required in this study since confidential patient information was already deleted. All reports followed the guidelines of Strengthening Epidemiological Observation and Research Report (STROBE).¹³ A Collaborative Institutional Training Initiative (CITI) license (Certificate No. 11326088) was obtained by Wang W, who was entitled to extract data from the MIMIC-IV database in accordance with the relevant regulations.

Participants

This study included patients who were admitted to the ICU and diagnosed with acute kidney injury (AKI) according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria.¹⁴ The definition of baseline serum creatinine level (SCr) in this study was based on two criteria: 1) the minimum SCr level recorded within 7 days before ICU admission, or 2) if there was no SCr data available before admission, the first SCr level measured upon admission to the ICU was used as the baseline.¹⁵ The study only considered data from the initial ICU admission for patients with multiple ICU stays. The MIMIC IV 2.0 database only contains data on adults older than 18. Patients who met any of the following criteria were excluded from the study: (1) death within 48 hours after admission to the ICU, (2) ICU stays less than 48 hours, and (3) missing more than 5% of potential risk variables that are associated with mortality.¹⁶ Covariates

The study included demographic characteristics and clinical characteristics with 24-hour average values. The Sequential Organ Failure Assessment (SOFA) score,¹⁷ and

Simplified Acute Physiology Score (SAPS) II,¹⁸ were calculated within the first 24 h after the ICU admission. During ICU admission, treatment measures (mechanical ventilation, continuous renal replacement therapy, vasopressors, sedative-analgesic medications, antibiotic and glucocorticoid use) were acquired (Table 1). These covariates, including clinical characteristics and basic demographic information, were based on other relevant studies.19

Table 1

Table 1		
Baseline characteris	tics	for the two groups before and after matching.

			-			
Characteristic Before PSM				After PSM		
	Non-DEX	DEX	SMD	Non- DEX	DEX	SMD
	(n=12536)	(n=3218)		(n=3196)	(n=3196)	
Age (y)	69.00 [58.00, 79.00]	63.00 [52.00,	0.377	64.00 [53.00, 73.00]	63.00 [52.00,	0.018
		73.00]			73.00]	
Gender			0.206			0.007
Male	6903 (55.1)	2095 (65.1)		2088 (65.3)	2077 (65.0)	
Female	5633 (44.9)	1123 (34.9)		1108 (34.7)	1119 (35.0)	
Laboratory measurements						
Hemoglobin (g/dL)	10.50 [8.90, 12.00]	10.40 [8.90,	0.012	10.40 [8.80, 12.10]	10.40 [8.90, 12.20]	0.004
		12.20]				
Platelet (10 ⁹ /L)	188.00 [137.00,	174.00	0.146	175.35 [127.48,	173.90 [130.31,	0.009
	247.54]	[130.37,		229.91]	229.50]	
		229.46]				
WBC (×10 ⁹)	11.10 [8.30, 14.70]	11.86 [9.00,	0.075	11.80 [8.70, 15.55]	11.86 [9.00, 15.48]	0.013
		15.50]				
Creatinine (mg/dL)	1.10 [0.80, 1.60]	1.00 [0.80,	0.108	1.00 [0.70, 1.50]	1.00 [0.80, 1.50]	0.001
		1.50]				
BUN (mg/dL)	21.00 [15.00, 35.00]	19.00 [14.00,	0.177	19.00 [13.00, 29.00]	19.00 [14.00,	0.006
		28.06]			28.06]	

BMJ Open

1 2 3 4	Lactate (mmol/L)	2.02 [1.41, 2.30]	1.83 [1.37,	0.051	1.88 [1.38, 2.43]	1.83 [1.37, 2.43]	0.019
5 6			2.43]				
7 8	Vital signs						
9 10	Weight (kg)	80.80 [68.00, 96.00]	86.00 [71.60,	0.095	85.00 [71.00, 100.00]	86.00 [71.60,	0.041
11			101.00]			101.00]	
12 13	T. (20)	26.02.526.57.27.001		0.200	26.00 [26.66.27.20]		0.022
14 15	Temperature (°C)	36.83 [36.57, 37.09]	36.91 [36.71,	0.289	36.88 [36.66, 37.29]	36.91 [36.71,	0.033
16			37.30]			37.29]	
17 18	Respiratory rate (bpm)	18.83 [16.68, 21.64]	19.09 [16.96,	0.069	18.97 [16.88, 21.72]	19.08 [16.95,	0.031
19 20			21.89]			21.87]	
21	Heart rate (bpm)	84.03 [74.35, 96.08]	84.47 [76.30,	0.074	84.74 [75.56, 97.25]	84.41 [76.28,	0.007
22 23			96.94]			96.85]	
24 25							
26	MAP (mmHg)	75.49 [69.80, 82.95]	75.66 [70.74,	0.004	75.74 [70.47, 82.39]	75.64 [70.73,	0.021
27 28			81.85]			81.84]	
29	Spo2 (%)	97.25 [95.77, 98.59]	97.60 [96.20,	0.131	97.72 [96.25, 98.93]	97.61 [96.20,	0.031
30 31			98.77]			98.77]	
32 33	Ethnicity			0.096			0.012
34				0.090			0.012
35 36	White	8516 (67.9)	2039 (63.4)		2048 (64.1)	2030 (63.5)	
37	other	4020 (32.1)	1179 (36.6)		1148 (35.9)	1166 (36.5)	
38 39	Admission type			0.223			0.018
40 41	Emergency	6720 (53.6)	1369 (42.5)		1393 (43.6)	1365 (42.7)	
42 43	other	5816 (46.4)	1849 (57.5)		1803 (56.4)	1831 (57.3)	
44	Need of support						
45 46							
47	Vasopressors	1221 (9.7)	600 (18.6)	0.257	554 (17.3)	596 (18.6)	0.034
48 49	MV	2977 (23.7)	1069 (33.2)	0.211	1122 (35.1)	1068 (33.4)	0.036
50 51	CRRT	768 (6.1)	367 (11.4)	0.187	333 (10.4)	363 (11.4)	0.03
52 53	Comorbidities at ICU						
54 55	admission						
56 57	Congestive heart failure	4314 (34.4)	951 (29.6)	0.104	924 (28.9)	948 (29.7)	0.017
57 58 59	Cerebrovascular disease	2139 (17.1)	504 (15.7)	0.038	506 (15.8)	502 (15.7)	0.003

Protec	
rotected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	Enseignement Superieur (ABES) .

Chronic pulmonary	3331 (26.6)	914 (28.4)	0.041	901 (28.2)	907 (28.4)	0.004
Renal disease	3143 (25.1)	602 (18.7)	0.154	610 (19.1)	598 (18.7)	0.01
Liver disease	1701 (13.6)	488 (15.2)	0.046	504 (15.8)	487 (15.2)	0.015
Diabetes	4023 (32.1)	984 (30.6)	0.033	971 (30.4)	979 (30.6)	0.005
Severity of illness						
SOFA score	6.00 [3.00, 8.00]	8.00 [5.00	, 0.451	7.00 [5.00, 11.00]	8.00 [5.00, 11.00]	0.027
		11.00]				
Respiration	0.00 [0.00, 2.00]	3.00 [0.00	, 0.596	2.00 [0.00, 3.00]	3.00 [0.00, 3.00]	0.028
		3.00]				
Cardiovascular	1.00 [1.00, 3.00]	1.00 [1.00	, 0.29	1.00 [1.00, 4.00]	1.00 [1.00, 4.00]	0.015
		4.00]				
Renal	1.00 [0.00, 2.00]	0.00 [0.00	, 0.11	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.016
		1.00]				
Nervous	1.00 [0.00, 2.00]	2.00 [1.00	, 0.343	2.00 [1.00, 3.00]	2.00 [1.00, 3.00]	0.018
		3.00]				
Liver	0.00 [0.00, 0.00]	0.00 [0.00	, 0.008	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	< 0.00
		0.00]				1
Coagulation	0.00 [0.00, 1.00]	0.00 [0.00	, 0.156	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.001
		1.00]				
SAPS II score	39.00 [31.00, 48.00]	40.00 [32.00	, 0.089	40.00 [31.00, 50.00]	40.00 [32.00,	0.003
		50.00]			50.00]	
Sedative-analgesic						
medications						
Propofol	6289 (50.2)	2924 (90.9)	0.997	2902 (90.8)	2902 (90.8)	< 0.00
						1
Midazolam	3049 (24.3)	1262 (39.2)	0.324	1234 (38.6)	1246 (39.0)	0.008
Fentanyl	6018 (48.0)	2586 (80.4)	0.717	2601 (81.4)	2564 (80.2)	0.029
AKI stage			0.063			0.034
1	6722 (53.6)	1826 (56.7)		1812 (56.7)	1810 (56.6)	

2	4593 (36.6)	1102 (34.2)		1123 (35.1)	1096 (34.3)	
3	1221 (9.7)	290 (9.0)		261 (8.2)	290 (9.1)	
Sepsis	8011 (63.9)	2590 (80.5)	0.377	2550 (79.8)	2568 (80.4)	0.014
Antibiotic	9852 (78.6)	3016 (93.7)	0.449	2991 (93.6)	2994 (93.7)	0.004
Glucocorticoid	2186 (17.4)	544 (16.9)	0.014	530 (16.6)	543 (17.0)	0.011
Outcome						
In-hospital mortality	1930 (15.4)	432 (13.4)		563 (17.6)	431 (13.5)	
180-day mortality	3725 (29.7)	704 (21.9)		868 (27.2)	703 (22.0)	

Values are expressed as M±SD/median (IQR) or n (%).

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; WBC, white blood cell; MAP, *Mean arterial pressure*; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Definitions and Outcomes

DEX use was defined as patients who received any dexmedetomidine treatment throughout hospitalization in the ICU, whatever the dosage. The primary outcome was in-hospital mortality and 180-day mortality of AKI patients in the ICU. Statistical analysis

Our study presented continuous variables are described as mean ± standard deviaton for normally distributed or as the median and interquartile range (IQR) if not normally distributed, while the t-test or Mann-Whitney U test was utilized for comparison between groups, respectively. Categorical variables were presented using numbers and percentages (%), and the chi-square test or Fisher's exact test was adopted from group comparisons. We used propensity score matching (PSM) by 1:1 nearest neighbor matching to adjust the baseline difference between the groups. The caliper value was set to 0.2 between matching participants. The standardized mean difference (SMD) was calculated to determine the balance within the model (Table 1), and SMD greater than 0.1 was considered unbalanced.²⁰

We used cox proportional hazards regression to assess the effect of DEX use on in-hospital mortality and 180-day mortality. Parameters with a p-value < 0.1 during univariate analysis and potential confounding factors were included in the multivariate

regression model. In the subgroup analysis, we classified patients based on age, gender, AKI stage, and sepsis incidence to assess the reliability of our findings. We conducted all statistical analyses using either R version 4.1.2, GraphPad Prism 6 software and MedCalc 20.1. The significance level was set at P < 0.05.

Results

Baseline population characteristics

15754 individuals diagnosed with AKI after ICU admission within 48h were selected for this analysis after excluding patients based on the exclusion criteria and classified in non-dexmedetomidine (non-DEX, n=12536) and dexmedetomidine (DEX, n=3218) groups (Fig.1). After PSM, the characteristics of 3196 patients in both groups were comparable (SMD< 0.1) (Table 1).

As presented in table 1, there were meaningful differences in age, gender, laboratory measurements, vital signs, admission type between the DEX group and the non-DEX group in the whole cohort. DEX treatment was more common in men and younger.

Primary Outcome

In-hospital mortality: We found that DEX use decreased in-hospital mortality risk by 38% among critically ill patients with AKI (HR: 0.62, 95% CI: 0.55-0.70) during PSM modeling and Cox proportional hazards regression (HR: 0.61, 95% CI: 0.55-0.68) (Fig.2, Supplementary table 1). A significant decrease in in-hospital mortality was observed among critically ill patients receiving DEX at AKI stage 1 (15.6% vs. 10.7%, p< 0.001), stage 2 (18.5% vs. 14.7%, p= 0.017) but not stage 3 (27.6% vs. 26.6%, p=0.848) (Fig.3).

180-day mortality: DEX use also reduced 180-day mortality risk by 22% among critically ill patients with AKI (HR: 0.77, 95% CI: 0.69-0.85) during PSM modeling and Cox proportional hazards regression (HR: 0.68, 95% CI: 0.63-0.74) (Fig.2, Supplementary table 2). A significant decrease in 180-day mortality was observed among critically ill patients receiving DEX at AKI stage 1 (24.7% vs. 18.2%, p< 0.001), stage 2 (28.3% vs. 24.0%, p= 0.023) but not stage 3 (39.1% vs. 38.3%, p= 0.861) (Fig.3).

We also investigated the in-hospital and 180-day survival in critically patients

BMJ Open

with AKI. The DEX group had significantly higher freedom from death at in-hospital (86.5 vs. 82.4%, p < 0.001) and 180-day (78.0 vs. 72.8%, p < 0.001) than the non-DEX group, respectively (Fig.4).

Overall, the use of DEX had a significant beneficial effect on the in-hospital mortality and 180-day mortality of AKI in critically ill patients.

Subgroup analysis

Subgroup analysis indicated that DEX use reduced in-hospital mortality of critically ill patients with AKI (Supplementary figure 1). There were no interactions between age, gender, sepsis, AKI stage, and DEX use, suggesting that these results were comparable for all populations.

Discussion

The present study showed that DEX use in severely ill AKI patients was linked with lower risk-adjusted in-hospital mortality and 180-day mortality. Consistent results were observed in different models. During subgroup analysis, after stratification according to age, gender, AKI stage, and sepsis, a strong correlation was still observed. Overall, we provide preliminary evidence that DEX has a beneficial effect on the prognosis of AKI in critically ill patients, providing the foothold to improve the outcomes of this patient population.

Overwhelming literature substantiates that DEX can alleviate AKI caused by several factors. Wang et al. previously uncovered that DEX could ameliorate AKI in mice with sepsis by partially inhibiting oxidative stress and apoptosis by modulating the p75NTR/p38MAPK/JNK signaling pathways.²¹ Zhao et al. further substantiated that DEX protected against lipopolysaccharide-induced AKI by promoting autophagy mediated by PI3K/AKI/mTOR pathway inhibition.²² A meta-analysis by Loomba et al. demonstrated that DEX could confer postoperative renal protective effects with lower NGAL levels and increased creatine clearance in patients who received DEX. These effects correlated with reduced ICU length of stay and risk of AKI and mortality.²³ Shan et al. found that DEX could minimize AKI incidence in Stanford type B aortic dissection (TBAD) patients after endovascular aortic repair (EVAR).²⁴ A single-center RCT of 108 patients²⁵ showed that prior administration of DEX within 24 hours after

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

induction of anesthesia could reduce the incidence of AKI after aortic surgery under cardiopulmonary bypass. An RCT by Tang et al.²⁶ showed that DEX pretreatment attenuated AKI in patients. Animal studies further indicated that DEX could reduce cellular injury, improve renal function, and mitigate apoptosis in renal cells. Furthermore, Liu et al. revealed that DEX infusion in ICU patients with septic shock was linked to decreased AKI incidence and reduced ICU stay and CRRT performance. It is highly conceivable that the mechanism is related to anti-inflammatory effects and immunomodulation.²⁷

Inflammation is key to AKI pathogenesis, progression, and prognosis. An increasing body of evidence suggests that DEX confers renoprotective effects and may be involved in the regulation of inflammation.²⁸⁻³⁰ A meta-analysis by Ma et al.³¹ that included 4842 patients showed that DEX decreased pro-inflammatory like cytokines interleukin-6, C-reactive, tumor necrosis factor- α , and increased anti-inflammatory cytokines like IL-10 in surgical patients. A sub-analysis of a multicenter RCT by Ohta et al.³² suggested that sedation using DEX reduced inflammation in patients with sepsis requiring mechanical ventilation. Animal studies have shown that DEX may have a protective effect on cisplatin-induced AKI, and its potential mechanism may be related to the regulation of apoptosis and inflammatory response.³³ In addition, DEX can ameliorate microcirculation disorders by decreasing norepinephrine levels in the blood and increasing urine output and renal blood flow.³⁴ Since our study did not collect inflammatory indicators, the hypothesis that DEX may attenuate excessive inflammation could not be confirmed, emphasizing the need for future studies. Emerging evidence substantiates the benefits of DEX in AKI, but the prognosis and follow-up of AKI in critically ill patients have been largely understudied. In the present study, we consistently found that the in-hospital mortality of AKI patients in the DEX group was significantly lower than in the non-DEX group. At the same time, we found that the 180-day mortality of AKI patients was consistent with the in-hospital mortality, suggesting that DEX use is associated with survival benefits in this particular patient population. Our research provides a theoretical basis for clnicians to use DEX to manage critically ill patients with AKI.

Our subgroup analysis showed that DEX was effective in sepsis-associated-AKI (SA-AKI) patients, consistent with the literature.³⁵ Consistently, Hu et al. analyzed 2192 patients with SA-AKI and found that DEX use was related to decreased in-hospital mortality and improved renal function recovery of SA-AKI in critically ill patients. Unlike Hu's study is that our study included all types of AKI populations in the ICU. Our results showed that DEX use reduced in-hospital mortality of AKI in critically ill patients. Follow-up analysis showed that DEX use reduced the 180-day mortality of patients. Our findings suggest DEX is effective against sepsis-associated AKI and for AKI patients in general and improves the long-term prognosis. The role of DEX on more types of AKI subgroups warrants further exploration in severely ill subjects.

Our research has several limitations. First, data acquired from this database was adopted to maximize generalizability and power. Accordingly, there was no formal calculation of sample size in this study. Although the sample size of the subgroup was comparatively larger compared to previous studies, it may also increase the risk of false positive results during multiple subgroup analyses. In addition, our study's retrospective nature may have limited our findings' accuracy, and there could be other unknown potential confounding factors that we were unable to control for. However, we adjusted for many confounding factors, and PSM was conducted. Moreover, data analyzed in this study were acquired from a single-center observation database, emphasizing the need for a multicenter RCT to increase the robustness of our findings.

Conclusion

This retrospective cohort study showed that dexmedetomidine administration significantly reduces risk-adjusted in-hospital and 180-day mortality in critically ill patients with AKI. However, further RCTs are needed to develop the robustness of our findings.

Reference:

[1] Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

concern. Lancet 2013; 382: 170-179. doi:10.1016/S0140-6736(13)60647-9 [2] Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41: 1411-1423. doi:10.1007/s00134-015-3934-7 [3] Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012; 81: 819-25. doi:10.1038/ki.2011.339 [4] Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core curriculum 2018. Am J Kidney Dis 2018; 72: 136–48.doi:10.1053/j.ajkd.2017.11.021 [5] Altshuler J, Spoelhof B. Pain, agitation, delirium, and neuromuscular blockade: a review of basic pharmacology, assessment, and monitoring. Crit Care Nurs Q 2013;36: 356-69.doi:10.1097/CNQ.0b013e3182a10dbf [6] Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anaesthesiol 2011;28: 3-6.doi:10.1097/EJA.0b013e32833e266d [7] Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41: 263–306.doi:10.1097/CCM.0b013e3182783b72 [8] Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med 2004; 30: 2188-2196.doi:10.1007/s00134-004-2417-z [9] Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis. Br J Anaesth 2019; 123: 777-94.doi:10.1016/j.bja.2019.07.027 [10] Shan XS, Dai HR, Zhao D, et al. Dexmedetomidine reduces acute kidney injury after endovascular aortic repair of Stanford type B aortic dissection: A randomized, double-blind, placebo-controlled pilot study. J Clin Anesth 2021; 75: 110498. doi:10.1016/j.jclinane.2021.110498 [11] Zhai M, Kang F, Han M, et al. The effect of dexmedetomidine on renal function in patients undergoing cardiac valve replacement under cardiopulmonary bypass: A double-blind randomized controlled trial. J Clin Anesth 2017; 40:33-38.

doi:10.1016/j.jclinane.2017.03.053

1	
2	
3	
4	
5	
6	
7	
, 8	
o 9	
9	
10	
11	
12	
13	
12 13 14 15 16 17	
15	
16	
17	
18	
19	
20	
20	
21 22 23 24	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
54 25	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
47 48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

[12] Johnson A, Bulgarelli L, Pollard T, et al. MIMIC-IV (version 2.0). PhysioNet.
2022. Available from: https://doi.org/10.13026/7vcr-e114.
[13] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) Statement: guidelines for
reporting observational studies. Int J Surg 2014; 12: 1495-
1499.doi:10.1016/j.ijsu.2014.07.013
[14] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron
Clin Pract 2012; 120: c179-84. doi:10.1159/000339789
[15] De Rosa S, Samoni S, Ronco C. Creatinine-based definitions: from baseline
creatinine to serum creatinine adjustment in intensive care. Crit Care 2016; 20: 69.
doi:10.1186/s13054-016-1218-4
[16] Zhao G-J, Xu C, Ying J-C, et al. Association between furosemide administration
and outcomes in critically ill patients with acute kidney injury. Crit Care 2020; 24: 75.
doi:10.1186/s13054-020-2798-6
[17]Vincent J-L, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess
the incidence of organ dysfunction/failure in intensive care units: results of a
multicenter, prospective study. Crit Care Med 1998; 26: 1793-800.
doi:10.1097/00003246-199811000-00016
[18] Sánchez-Díaz JS, Escarraman-Martínez D, Guerrero-Gutiérrez MA, et al.
Simplified acute physiology score II and Mannheim peritonitis index are associated
with in-hospital mortality in patients with abdominal sepsis admitted to ICU.
Simplified acute physiology score II y Mannheim peritonitis index se asocian a
mortalidad intrahospitalaria en pacientes con sepsis abdominal ingresados a la UCI.
Cir Cir 2022; 90: 81-91. doi:10.24875/CIRU.22000219
[19] Senda A, Endo A, Tachimori H, et al. Early administration of glucocorticoid for
thyroid storm: analysis of a national administrative database. Crit Care 2020; 24: 470.
doi:10.1186/s13054-020-03188-8
[20] Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the
assessment of measured covariate balance to test causal associations in psychological
research. Psychol Methods 2015; 15: 234-63. doi:10.1037/a0019623

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

[21] Wang Z, Wu J, Hu Z, et al. Dexmedetomidine Alleviates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting p75NTR-Mediated Oxidative Stress and Apoptosis. *Oxid Med Cell Longev* 2020; 2020: 5454210. doi:10.1155/2020/5454210
[22] Zhao Y, Feng X, Li B, et al. Dexmedetomidine Protects Against Lipopolysaccharide-Induced Acute Kidney Injury by Enhancing Autophagy Through

Inhibition of the PI3K/AKT/mTOR Pathway. *Front Pharmacol* 2020; 11: 128. doi:10.3389/fphar.2020.00128

[23] Loomba RS, Villarreal EG, Dhargalkar J, et al. The effect of dexmedetomidine on renal function after surgery: A systematic review and meta-analysis. *J Clin Pharm Ther* 2022; 47: 287-297. doi:10.1111/jcpt.13527.

[24] Shan XS, Dai HR, Zhao D, et al. Dexmedetomidine reduces acute kidney injury after endovascular aortic repair of Stanford type B aortic dissection: A randomized, double-blind, placebo-controlled pilot study. *J Clin Anesth* 2021; 75: 110498.

doi:10.1016/j.jclinane.2021.110498

[25] Soh S, Shim JK, Song JW, et al. Effect of dexmedetomidine on acute kidney injury after aortic surgery: a single-centre, placebo-controlled, randomised controlled trial. Br J Anaesth 2020; S0007-0912 (20) 30001-5.doi:10.1016/j.bja.2019.12.036
[26] Tang C, Hu Y, Gao J, et al. Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat. Life Sci 2020; 257: 118004. doi:10.1016/j.lfs.2020.118004

[27] Liu J, Shi K, Hong J, et al. Dexmedetomidine protects against acute kidney injury in patients with septic shock. *Ann Palliat Med* 2020; 9: 224-230.

doi:10.21037/apm.2020.02.08

[28] Zhang J, Bi J, Ren Y, et al. Involvement of GPX4 in irisin's protection against ischemia reperfusion-induced acute kidney injury. J Cell Physiol 2021; 236: 931-945. doi:10.1002/jcp.29903

[29] Zhao M, Wang Y, Li L, et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAMmediated mtDNA maintenance. Theranostics 2021; 11: 1845-1863.

BMJ Open

doi:10.7150/thno.50905
[30] Hasegawa S, Inoue T, Nakamura Y, et al. Activation of Sympathetic Signaling in
Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-
Reperfusion Injury. J Am Soc Nephrol 2021; 32, 1599–1615.
doi:10.1681/ASN.2020121723
[31] Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress,
inflammation, and immune function: systematic review and meta-analysis. Br J
Anaesth 2019; 123: 777-794. doi:10.1016/j.bja.2019.07.027
[32] Ohta Y, Miyamoto K, Kawazoe Y, et al. Effect of dexmedetomidine on
inflammation in patients with sepsis requiring mechanical ventilation: a sub-analysis
of a multicenter randomized clinical trial. Crit Care 2020; 24: 493.
doi:10.1186/s13054-020-03207-8
[33] Liang H, Liu HZ, Wang HB, et al. Dexmedetomidine protects against cisplatin-
induced acute kidney injury in mice through regulating apoptosis and inflammation.
Inflamm Res 2017; 66: 399-411. doi:10.1007/s00011-017-1023-9
[34] Ebert Thomas J, Hall Judith E, Barney Jill A, et al. The effects of increasing
plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93:
382–94. doi:10.1097/00000542-200008000-00016
[35] Hu H, An S, Sha T, et al. Association between dexmedetomidine administration
and outcomes in critically ill patients with sepsis-associated acute kidney injury. J
Clin Anesth 2022; 83: 110960. doi:10.1016/j.jclinane.2022.110960
Figure Legends:
Fig.1. Flowchart of patients selection for the study. MIMIC-IV: Medical Information Mart for
Intensive Care Database IV; ICU: intensive care unit.
Fig.2. Association between in-hospital mortality, 180-day mortality and dexmedetomidine use of
AKI patients evaluated by the Cox model. HR, hazard ratio; CI: confidence interval; Unadjusted:
without adjustment; Multivarable adjusted: adjusted for all the baseline variables shown in Table 1.

PSM: propensity score matching.


Fig.3. In-hospital mortality and 180-day mortality of AKI in critically ill patients between the


dexmedetomidine and non-dexmedetomidine group in different AKI stage.

Fig.4. Freedom from death at in-hospital and 180-day in critically ill patients with AKI between the two groups.

Supplementary figure 1. Subgroup analysis of the association between dexmedetomidine use and in-hospital mortality.

to occure with









Fig.2. Association between in-hospital mortality, 180-day mortality and dexmedetomidine use of AKI patients evaluated by the Cox model. HR, hazard ratio; CI: confidence interval; Unadjusted: without adjustment; Multivarable adjusted: adjusted for all the baseline variables shown in Table 1. PSM: propensity score matching.

338x190mm (96 x 96 DPI)






Fig.4. Freedom from death at in-hospital and 180-day in critically ill patients with AKI between the two groups.

338x190mm (96 x 96 DPI)

Supplementary table 1.

Cox logistic regression analysis of in-hospital mortality (before PSM)

	Univar	iable		Multivariable	Multivariable	
Variables	OR (95	%CI)	<i>P</i> value	OR (95%CI)	P value	
Need of support						
Vasopressors	2.636	(2.415,	<0.001	1.394 (1.251, 1.553)	< 0.001	
	2.877)					
MV	4.108	(3.782,	< 0.001	4.090 (3.710, 4.509)	< 0.001	
	4.462)					
CRRT	1.863	(1.680,	< 0.001	0.845 (0.750, 0.952)	0.006	
	2.065)					
Comorbidities at ICU						
admission						
Congestive heart failure	1.151	(1.058,	0.001	1.229 (1.125, 1.342)	< 0.001	
	1.251)					
Cerebrovascular disease	1.437	(1.307,	<0.001	1.547 [1.403, 1.705]	< 0.001	
	1.581)					
Chronic pulmonary	1.056	(0.965,	0.237			
	1.155)					
Renal disease	1.101	(1.005,	0.040	1.025 [0.928, 1.132]	0.629	
	1.206)					
Liver disease	1.651	(1.505,	<0.001	1.120 (1.009, 1.244)	0.033	
	1.812)					
Diabetes	0.901	(0.825,	< 0.001	0.818 [0.746, 0.898]	< 0.001	
	0.984)					
Severity of illness						
SOFA score	1.115	(1.105,	< 0.001	1.007 [0.993, 1.021]	0.350	
	1.125)					
SAPS II score	1.033	(1.031,	< 0.001	1.018 (1.015, 1.021)	< 0.001	

Page	24	of	28

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4 5
6
/
8 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
40 47
47 48
40 49
49 50
50 51
51 52
52 53
54
55
56
57
58
59
60

1

	1.036)			
Sedative-analgesic				
medications				
Propofol	0.788 (0.72	25, <0.001	0.465 (0.421, 0.513)	< 0.001
	0857)			
Midazolam	1.680 (1.54	47, <0.001	0.838 (0.758, 0.928)	0.001
	1.823)			
Fentanyl	1.724 (1.50	58, <0.001	1.309 (1.154, 1.486)	< 0.001
	1.895)			
AKI stage				
AKI stage 1	Ref		Ref	
AKI stage 2	1.142 (1.07	71, <0.001	1.044 (0.955, 1.142)	0.342
	1.217)			
AKI stage 3	1.800 (1.64	46, <0.001	1.048 (0.928, 1.183)	0.453
	1.969)			
Lactate (mmol/L)	1.314 (1.29	92, <0.001	1.224 (1.199, 1.250)	< 0.001
	1.337)			
Sepsis	1.871 (1.67	70, <0.001	1.574 (1.304, 1.901)	<0.001
	2.096)			
Antibiotic	1.366 (1.19	91, <0.001	0.665 (0.533, 0.831)	< 0.001
	1.562)			
Glucocorticoid	0.719 (0.64	45, <0.001	0.709 (0.635, 0.791)	<0.001
	0.801)			
DEX	0.585 (0.52	26, <0.001	0.610 (0.546, 0.680)	< 0.001
	0.650)			

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Supplementary table 2.

Cox logistic regression analysis of 180-day mortality (before PSM)

	Univar	iable		Multivariable	
Variables	OR (95	5%CI)	<i>P</i> value	OR (95%CI)	P value
Need of support					
Vasopressors	2.771	(2.579,	<0.001	1.454 (1.331, 1.588)	< 0.001
	2.977)				
MV	2.626	(2.474,	<0.001	2.565 (2.390, 2.752)	< 0.001
	2.788)				
CRRT	2.554	(2.345,	<0.001	0.995 (0.899, 1.101)	0.920
	2.783)				
Comorbidities at ICU					
admission					
Congestive heart failure	1.318	(1.240,	<0.001	1.194 (1.120, 1.273)	< 0.001
	1.400)				
Cerebrovascular disease	1.423	(1.324,	<0.001	1.581 (1.469, 1.701)	< 0.001
	1.530)				
Chronic pulmonary	1.129	(1.058,	<0.001	1.104 (1.033, 1.180)	0.004
	1.204)				
Renal disease	1.379	(1.293,	<0.001	1.090 (1.017, 1.168)	0.015
	1.472)				
Liver disease	1.881	(1.749,	<0.001	1.249 (1.152, 1.355)	< 0.001
	2.022)				
Diabetes	0.982	(0.922,	0.580		
	1.046)				
Severity of illness					
SOFA score	1.129	(1.121,	<0.001	1.013 (1.001, 1.024)	0.029
	1.136)				
SAPS II score	1.039	(1.037,	<0.001	1.025 (1.023, 1.028)	<0.001

	1.041)				
Sedative-analgesic					
medications					
Propofol	0.715	(0.674,	<0.001	0.448 (0.418, 0.482)	<0.0
	0.758)				
Midazolam	1.809	(1.703,	< 0.001	0.910 (0.841, 0.986)	0.02
	1.923)				
Fentanyl	1.492	(1.404,	<0.001	1.242 (1.140, 1.352)	<0.0
	1.586)				
AKI stage					
AKI stage 1	Ref			Ref	
AKI stage 2	1.142	(1.071,	<0.001	1.076 (1.009, 1.148)	0.02
	1.217)				
AKI stage 3	1.800	(1.646,	<0.001	1.097 (0.999, 1.204)	0.05
	1.969)				
Lactate (mmol/L)	1.250	(1.232,	<0.001	1.155 (1.134, 1.176)	<0.0
	1.268)				
Sepsis	2.060	(1.915,	< 0.001	1.664 (1.478, 1.874)	<0.0
	2.215)				
Antibiotic	1.531	(1.404,	< 0.001	0.808 (0.703, 0.928)	0.00
	1.669)				
Glucocorticoid	1.162	(1.079,	<0.001	1.072 (0.994, 1.156)	0.07
	1.251)				
DEX	0.693	(0.639,	< 0.001	0.683 (0.626,0.744)	<0.0
	0.751)				

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Subgrou	p No. of Patients		OR (95% CI)	P for interaction
Age				0.6
≥60	10953	⊢ ∎1	0.69 (0.60-0.78)	
<60	4801	⊨−■−−1	0.445 (0.36-0.55)	
Gender				0.57
Female	6756	⊢■→	0.61 (0.53-0.71)	
Male	8998	⊢ _∎1	0.70 (0.59-0.83)	
AKI				0.69
Stage 1	8548	⊢-∎ 1	0.63 (0.53-0.74)	
Stage 2	5695	⊢ 4	0.70 (0.58-0.85)	
Stage 3	1511	⊢	0.62 (0.47-0.81)	
Sepsis				0.35
Yes	10601	⊢∎⊸1	0.66 (0.59-0.74)	
No	5153	⊢ I	0.51 (0.34-0.77)	
			1	
	-	.325 0.50.60.70.80.9		
	<dexmedetomidine be<="" td=""><td>etterNo</td><td>dexmedetomidine Bette</td><td>er></td></dexmedetomidine>	etterNo	dexmedetomidine Bette	er>

Supplementary figure 1. Subgroup analysis of the association between dexmedetomidine use and in-hospital mortality.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	1
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was	2
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	3
		reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of	4
-		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	4
		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	5
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	4
		effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	5
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	5
		describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	4
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	4
		(c) Explain how missing data were addressed	5
		(d) If applicable, explain how loss to follow-up was addressed	
		(<u>e</u>) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	6
		eligible, examined for eligibility, confirmed eligible, included in the study,	
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	Yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	6
		and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	6

BMJ Open

Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6
		(b) Report category boundaries when continuous variables were categorized	6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a	
		meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity	6
		analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	7
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	9
		Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,	9
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	8.9
Other informati	ion		
Funding	22	Give the source of funding and the role of the funders for the present study and, if	1
		applicable, for the original study on which the present article is based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

BMJ Open

The impact of dexmedetomidine on mortality in critically ill patients with acute kidney injury: A retrospective propensity score matching analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-073675.R1
Article Type:	Original research
Date Submitted by the Author:	11-Jul-2023
Complete List of Authors:	Wang, Wenting; Peking Union Medical College Jin, Yu; Peking Union Medical College Zhang, Peiyao; Peking Union Medical College Gao, Peng; Peking Union Medical College Wang, He; Peking Union Medical College, Department of Cardiopulmonary Bypass Liu, Jinping; Peking Union Medical College Hospital, Department of Cardiopulmonary Bypass
Primary Subject Heading :	Intensive care
Secondary Subject Heading:	Medical management, Renal medicine
Keywords:	INTENSIVE & CRITICAL CARE, Acute renal failure < NEPHROLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Page 2 of 43

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

2	
3	
4	
5	
6	
6 7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
16 17	
18	
19	
20	
20 21 22 23	
27	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1	The impact of dexmedetomidine on mortality in critically ill patients with
2	acute kidney injury: A retrospective propensity score matching analysis
3	
4	Authors: Wenting Wang ¹ , Yu Jin ¹ , Peiyao Zhang ¹ , Peng Gao ¹ , He Wang ¹ , Jinping
5	Liu ¹ *
6	
7	Institutions: ¹ Department of Cardiopulmonary Bypass, State Key Laboratory of
8	Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular
9	Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College,
10	Beijing, China
11	
12	Corresponding Author: Jinping Liu; Fuwai hospital, No.167, North Lishi Road,
13	Xicheng District, 100037, Beijing, China; E-mail: liujinping@fuwai.com; TEL: 010-
14	88396257, FAX: 010-88396257.
15	
16	Abstract:
17	Objectives This study sought to estimate the effect of dexmedetomidine (DEX)
18	administration on mortality in critically ill patients with acute kidney injury (AKI).
19	Design A retrospective cohort study.
20	Setting The study sourced its data from the Multiparameter Intelligent Monitoring in
21	Intensive Care Database IV (MIMIC-IV), a comprehensive database of ICU patients.
22	Participants A total of 15754 critically ill patients with AKI were enrolled from the
23	MIMIC-IV database.
24	Primary and secondary outcome Primary outcome was in-hospital mortality and
25	secondary outcome was 180-day mortality.
26	Results 15754 critically ill AKI patients were included in our analysis. We found that
27	DEX use decreased in-hospital mortality risk by 38% (HR: 0.62, 95% CI: 0.55-0.70).
28	A significant decrease in in-hospital mortality was observed following treatment with
29	DEX among critically ill patients with AKI stage 1 (15.6% vs. 10.7%, p< 0.001), stage

30	2 (18.5% vs. 14.7%, p = 0.017) but not stage 3 (27.6% vs. 26.6%, p = 0.848). Moreover,
31	the 180-day mortality was reduced at AKI stage 1 (24.7% vs. 18.2%) and stage 2 (28.3%
32	vs. 24.0%) but not stage 3 (39.1% vs. 38.3%).
33	Conclusions Our retrospective cohort study suggests that DEX significantly correlates
34	with decreased risk-adjusted in-hospital and 180-day mortality in critically ill AKI
35	patients. Nonetheless, future randomized controlled trials (RCTs) are warranted to
36	validate our findings.
37	Keywords: Dexmedetomidine, AKI, Mortality, MIMIC-IV, Propensity score matching
38	
39	
40	Strengths and limitations of this study
41	• This study included 15754 patients, which is a very large sample size for a
42	clinical study of critically ill patients with AKI.
43	• Additional confounding factors were adjusted and increased the reliability of
44	our results and conducted a subgroup analysis of the association between DEX
45	use and in-hospital mortality.
46	• This was a retrospective design without long-term follow-up, so the results
47	may be biased.
48	• The data of this study was from a MIMIC-IV database, and some data may be
49	missing which slightly offsets the results.
50	
51	
52	
53	
54	
55	
56	
50	more than har of patients experience rise during their stay in the intensive care unit

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

(ICU).² AKI is related to adverse outcomes, increases CKD occurrence and kidney
replacement therapy, and raises the risk of short- and long-term deaths,³ causing huge
social and economic burdens to patients and society. However, further research is
warranted to optimize the management of AKI.⁴

In the context of critical care, effective sedation is of utmost importance for managing agitation and anxiety in patients.⁵ The primary objective of sedation in the ICU is to achieve a state of calmness and cooperation in the patient, allowing for the easy awakening and clear communication of needs, particularly concerning pain management.⁶ There is evidence to suggest that maintaining light sedation in patients in the ICU can lead to better outcomes. Current guidelines recommend dexmedetomidine (DEX) for sedation in an intensive care setting.⁷ DEX is widely used in ICU as a highly selective alpha-2 agonist.⁸ An increasing body of evidence suggests that DEX can inhibit the production of excess inflammation cytokine and protect renal function, which may positively impact the prognosis of AKI.9-11 However, the renoprotective effects of DEX in critically ill patients have not been explored, based on the above characteristics of DEX, we assume that the use of DEX can reduce the mortality rate of AKI patients. The current literature consists mainly of basic-level studies or small samples of other population cohorts, with a paucity of large-scale research¹²⁻¹³. Hence, the present study aims to investigate DEX's effect on AKI-related mortality in critically ill patients based on a large sample of critical care public databases.

78 Methods

79 Data sources

The study sourced its data from the Multiparameter Intelligent Monitoring in Intensive Care Database IV (MIMIC-IV), a comprehensive database of ICU patients.¹⁴ We collected data on AKI patients from the MIMIC-IV database treated with or without DEX. This database contains a publicly available and real-world clinical database of patients at the Beth Israel Deaconess Medical Center from 2008 to 2019. Informed consent of patients was not required in this study since confidential patient information was already deleted. All reports followed the guidelines of Strengthening

87 Epidemiological Observation and Research Report (STROBE).¹⁵ A Collaborative
88 Institutional Training Initiative (CITI) license (Certificate No. 11326088) was obtained
89 by Wang W, who was entitled to extract data from the MIMIC-IV database in
90 accordance with the relevant regulations.

Participants

This study included patients who were admitted to the ICU and diagnosed with acute kidney injury (AKI) according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria.¹⁶ The definition of baseline serum creatinine level (SCr) in this study was based on two criteria: 1) the minimum SCr level recorded within 7 days before ICU admission, or 2) if there was no SCr data available before admission, the first SCr level measured upon admission to the ICU was used as the baseline.¹⁷ The MIMIC IV 2.0 database only contains data on adults older than 18. Patients who met any of the following criteria were excluded from the study: (1) death within 48 hours after admission to the ICU, (2) ICU stays less than 48 hours.

101 Covariates

The study included demographic characteristics and clinical characteristics with 24-hour average values. The Sequential Organ Failure Assessment (SOFA) score,¹⁸ and Simplified Acute Physiology Score (SAPS) II,¹⁹ were calculated within the first 24 h after the ICU admission. We collected the following clinical information of each patient: demographics, laboratory measurements, vital signs, ethnicity, admission type, need of support, comorbidities at ICU admission, severity of illness, sedative-analgesic medications use, AKI stage, sepsis, antibiotic use, glucocorticoid use(Table 1). These covariates, including clinical characteristics and basic demographic information, were based on other relevant studies and clinical practice.²⁰⁻²¹

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

111 Data definitions

Extracted data from MIMIC-IV on the first day of ICU admission, including age,
gender, laboratory measurements, vital signs, ethnicity, admission type, vasopressors,
mechanical ventilation (MV), continuous renal replacement therapy (CRRT),
comorbidities, SOFA score, SAPS II score. We also collected information on whether
DEX, propofol, midazolam, fentanyl, antibiotics, and glucocorticoids were used during

Page 6 of 43

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

> 117 ICU hospitalization. Sepsis was defined as a life-threatening organ dysfunction caused 118 by a dysregulation of host response to infection (Sepsis 3.0)²², which refers to patients 119 with documented or suspected infections and acute changes in the SOFA score ≥ 2 120 points.

> 121 DEX use was defined as patients who received any dexmedetomidine treatment 122 throughout hospitalization in the ICU.

123 Outcomes

124 In-hospital mortality refers to the death of patients during this hospitalization, 125 which was recorded by the hospital²³. In the MIMIC-IV database, this type of patients 126 will be marked with a 'hospital expire flag' to indicate the hospital death during this 127 hospitalization. If a patient has been hospitalized multiple times, we only select the first 128 check-in record. The primary outcome was in-hospital mortality and the second 129 outcome was 180-day mortality of AKI patients in the ICU.

130 Statistical analysis

Our study presented continuous variables described as mean±standard deviaton for normally distributed or as the median and interguartile range (IQR) if not normally distributed, while the t-test or Mann-Whitney U test was utilized for comparison between groups, respectively. Categorical variables were presented using numbers and percentages (%), and the chi-square test or Fisher's exact test was adopted from group comparisons. We used propensity score matching (PSM) by 1:1 nearest neighbor matching to adjust the baseline difference between the groups. The caliper value was set to 0.2 between matching participants. The standardized mean difference (SMD) was calculated to determine the balance within the model (Table 1), and SMD greater than 0.1 was considered unbalanced.24

We used Cox proportional hazards regression and binary logistic regression to
assess the effect of DEX use on in-hospital mortality and 180-day mortality. In the
subgroup analysis, we used binary logistic regression analysis of in-hospital mortality
to assess the effect of DEX use on in-hospital mortality in subgroup populations.
Parameters with a p-value< 0.1 during univariate analysis and potential confounding

factors were included in the multivariate regression model. In the subgroup analysis,
we classified patients based on age, gender, AKI stage, and sepsis incidence to assess
the reliability of our findings. We conducted all statistical analyses using either R
version 4.1.2, GraphPad Prism 6 software, or MedCalc 20.1. The significance level was
set at p< 0.05.

151 Patient and public involvement

152 None.

153 Results

154 Baseline population characteristics

155 15754 individuals diagnosed with AKI after ICU admission within 48h were 156 selected for this analysis after excluding patients based on the exclusion criteria 157 (Figure 1). In the whole cohort, the median age of patients was $68 (57 \pm 78)$ years old, 158 with 8998 (57.1%) males and 6756 (42.9%) females. 8548 (54.3%) patients were 159 diagnosed with AKI stage 1, 5695 (36.1%) with AKI stage 2, and 1511 (9.6%) with 160 AKI stage 3.

In this study, patients were classified into non-dexmedetomidine (non-DEX, n=12536) and dexmedetomidine (DEX, n=3218) groups. Compared with the non-DEX group, the DEX group was younger (63 vs 69 y, p < 0.001), heavier weight (86.0 vs 80.8 kg, p< 0.001), higher wbc (11.9 vs 11.1×10^9 , p< 0.001), temperature (36.9 vs 36.8 °C, p < 0.001), Spo2 (97.6 vs 97.3 %, p < 0.001), sofa score (8.0 vs 6.0, p < 0.001) and SAPS II score (40.0 vs 39.0, p< 0.001), faster respiratory rate (19.1 vs 18.8 bpm, p< 0.001) and heart rate (84.5 vs 84.0 bpm, p=0.001), lower platelet (174.0 vs 188.0 10⁹/L, p< 0.001), creatinine (1.0 vs 1.1 mg/dL, p< 0.001), bun (19.0 vs 21.0 mg/dL, p< 0.001), lactate (1.83 vs 2.02 mmol/L, p=0.001), congestive heart failure (29.6% vs 34.4%, p< 0.001) and renal disease (18.7% vs 25.1%, p< 0.001), more female (65.1% vs 55.1%, p < 0.001), white ethnicity (63.4% vs 67.9%, p < 0.001), emergency admission (42.5%) vs 53.6, p< 0.001), vasopressin use (18.6 vs 9.7 %, p< 0.001), MV (33.2% vs 23.7%, p < 0.001), CRRT (11.4% vs 6.1%, p < 0.001), chronic pulmonary (28.4% vs 26.6%, p =0.039), liver disease (15.2% vs 13.6%, p= 0.021), propofol use (90.0% vs 50.2%, p< (0.001), midazolam use (39.2% vs 24.3%, p < 0.001) fentanyl use (80.4% vs 48.0, p < 0.001)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

178 patients in both groups were comparable (SMD< 0.1) (Table 1). 179 Table 1. Baseline characteristics for the two groups before and after matching. After PSM Characteristic Before PSM Non-DEX DEX SMD Non- DEX DEX SMD (n=12536) (n=3218) (n=3196) (n=3196) 69.00 [58.00, 79.00] 63.00 [52.00, 73.00] 64.00 [53.00, 73.00] 63.00 [52.00, 73.00] 0.018 Age (y) 0.377 0.007 Gender, male, n (%) 6903 (55.1) 2095 (65.1) 0.206 2088 (65.3) 2077 (65.0) Laboratory measurements Hemoglobin (g/dL) 10.50 [8.90, 12.00] 10.40 [8.90, 12.20] 0.012 10.40 [8.80, 12.10] 10.40 [8.90, 12.20] 0.004 Platelet (×109/L) 188.00 [137.00, 247.54] 174.00 [130.37, 229.46] 0.146 175.35 [127.48, 229.91] 173.90 [130.31, 229.50] 0.009 WBC (×109) 11.86 [9.00, 15.50] 11.10 [8.30, 14.70] 0.075 11.80 [8.70, 15.55] 11.86 [9.00, 15.48] 0.013 Creatinine (mg/dL) 1.10 [0.80, 1.60] 1.00 [0.80, 1.50] 0.108 1.00 [0.70, 1.50] 1.00 [0.80, 1.50] 0.001 BUN (mg/dL) 21.00 [15.00, 35.00] 19.00 [14.00, 28.06] 19.00 [13.00, 29.00] 0.177 19.00 [14.00, 28.06] 0.006 1.83 [1.37, 2.43] 0.051 0.019 Lactate (mmol/L) 2.02 [1.41, 2.30] 1.88 [1.38, 2.43] 1.83 [1.37, 2.43] Vital signs 80.80 [68.00, 96.00] 86.00 [71.60, 101.00] 0.095 85.00 [71.00, 100.00] 86.00 [71.60, 101.00] 0.041 Weight (kg) 36.83 [36.57, 37.09] 36.91 [36.71, 37.30] 0.289 36.88 [36.66, 37.29] 36.91 [36.71, 37.29] 0.033 Temperature (°C) 18.83 [16.68, 21.64] 19.09 [16.96, 21.89] 0.069 18.97 [16.88, 21.72] 19.08 [16.95, 21.87] 0.031 Respiratory rate (bpm) Heart rate (bpm) 84.03 [74.35, 96.08] 84.47 [76.30, 96.94] 0.074 84.74 [75.56, 97.25] 84.41 [76.28, 96.85] 0.007 MAP (mmHg) 75.49 [69.80, 82.95] 75.66 [70.74, 81.85] 0.004 75.74 [70.47, 82.39] 75.64 [70.73, 81.84] 0.021 Spo2 (%) 97.25 [95.77, 98.59] 97.60 [96.20, 98.77] 0.131 97.72 [96.25, 98.93] 97.61 [96.20, 98.77] 0.031 Ethnicity, white, n (%) 8516 (67.9) 2039 (63.4) 0.096 2048 (64.1) 2030 (63.5) 0.012 0.018 Admission type, emergency, n 6720 (53.6) 1369 (42.5) 0.223 1393 (43.6) 1365 (42.7) (%) Need of support, n (%) 0.034 Vasopressors 1221 (9.7) 600 (18.6) 0.257 554 (17.3) 596 (18.6)

and antibiotics use (93.7% vs 78.6%, p < 0.001). After PSM, the characteristics of 3196

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

0.211

1122 (35.1)

1068 (33.4)

0.036

1069 (33.2)

57 58

59 60 MV

2977 (23.7)

Page 9	9 of 43
--------	---------

1 2							
3 4	CRRT	768 (6.1)	367 (11.4)	0.187	333 (10.4)	363 (11.4)	0.030
5 6	Comorbidities at ICU						
7 8	admission, n (%)						
9 10	Congestive heart failure	4314 (34.4)	951 (29.6)	0.104	924 (28.9)	948 (29.7)	0.017
11 12	Cerebrovascular disease	2139 (17.1)	504 (15.7)	0.038	506 (15.8)	502 (15.7)	0.003
13 14	Chronic pulmonary	3331 (26.6)	914 (28.4)	0.041	901 (28.2)	907 (28.4)	0.004
15 16	Renal disease	3143 (25.1)	602 (18.7)	0.154	610 (19.1)	598 (18.7)	0.010
17 18	Liver disease	1701 (13.6)	488 (15.2)	0.046	504 (15.8)	487 (15.2)	0.015
19 20	Diabetes	4023 (32.1)	984 (30.6)	0.033	971 (30.4)	979 (30.6)	0.005
20 21 22	Severity of illness						
22 23 24	SOFA score	6.00 [3.00, 8.00]	8.00 [5.00, 11.00]	0.451	7.00 [5.00, 11.00]	8.00 [5.00, 11.00]	0.027
25	SAPS II score	39.00 [31.00, 48.00]	40.00 [32.00, 50.00]	0.089	40.00 [31.00, 50.00]	40.00 [32.00, 50.00]	0.003
26 27	Sedative-analgesic						
28 29	medications, n (%)						
30 31	Propofol	6289 (50.2)	2924 (90.9)	0.997	2902 (90.8)	2902 (90.8)	< 0.001
32 33	Midazolam	3049 (24.3)	1262 (39.2)	0.324	1234 (38.6)	1246 (39.0)	0.008
34 35	Fentanyl	6018 (48.0)	2586 (80.4)	0.717	2601 (81.4)	2564 (80.2)	0.029
36 37	AKI stage, n (%)			0.063			0.034
38 39	1	6722 (53.6)	1826 (56.7)		1812 (56.7)	1810 (56.6)	
40 41	2	4593 (36.6)	1102 (34.2)		1123 (35.1)	1096 (34.3)	
42 43	3	1221 (9.7)	290 (9.0)		261 (8.2)	290 (9.1)	
44 45	Sepsis, n (%)	8011 (63.9)	2590 (80.5)	0.377	2550 (79.8)	2568 (80.4)	0.014
46 47	Antibiotic, n (%)	9852 (78.6)	3016 (93.7)	0.449	2991 (93.6)	2994 (93.7)	0.004
48 49	Glucocorticoid, n (%)	2186 (17.4)	544 (16.9)	0.014	530 (16.6)	543 (17.0)	0.011
50 51	Outcome, n (%)						
52 53	In-hospital mortality	1930 (15.4)	432 (13.4)		563 (17.6)	431 (13.5)	
54 55	180-day mortality	3725 (29.7)	704 (21.9)		868 (27.2)	703 (22.0)	
56	180 Values are exp	pressed as M±SD/median (IQR	.) or n (%).				
57	181 PSM, Propens	sity Score Matching; DEX, De	exmedetomidine; SAPS, Sin	nplified Acute	Physiology Score; WBC, whi	ite blood cell; MAP,	
58 59	182 Mean arteria	l pressure; SOFA, The Sequ	ential Organ Failure Asses	ssment; MV,	Mechanical ventilation; CRR	T, continuous renal	
60	183 rankaamant ti	harany: AVI A auto kidnay dia					

60 183 replacement therapy; AKI, Acute kidney disease.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1 2		
- 3 4	184	
5 6	185	Primary Outcome
7 8	186	In-hospital mortality: We found that DEX use decreased in-hospital mortality risk
9 10	187	by 38% among critically ill patients with AKI (HR: 0.62, 95% CI: 0.55-0.70) during
11 12	188	PSM modeling. Moreover, Cox proportional hazards regression (HR: 0.61, 95% CI:
13 14	189	0.55-0.68) (Fig.2, Supplementary table 1) and binary logistic regression (OR: 0.64, 95%
15 16	190	CI: 0.56-0.73) (Supplementary table 2) were consistent with the trend of PSM modeling.
17 18	191	A significant decrease in in-hospital mortality was observed among critically ill patients
19 20	192	receiving DEX at AKI stage 1 (15.6% vs. 10.7%, p< 0.001), stage 2 (18.5% vs. 14.7%,
21 22	193	p= 0.017) but not stage 3 (27.6% vs. 26.6%, p= 0.848) (Fig.3).
23 24	194	Second Outcome
25 26	195	180-day mortality: DEX use also reduced 180-day mortality risk by 22% among
20 27 28	196	critically ill patients with AKI (HR: 0.77, 95% CI: 0.69-0.85) during PSM modeling.
29 30	197	Moreover, Cox proportional hazards regression (HR: 0.68, 95% CI: 0.63-0.74) (Fig.2,
31 32	198	Supplementary table 3) and binary logistic regression (OR: 0.64, 95% CI: 0.57-0.71)
33	199	(Supplementary table 4) were consistent with the trend of PSM modeling. A significant
34 35	200	decrease in 180-day mortality was observed among critically ill patients receiving DEX
36 37	201	at AKI stage 1 (24.7% vs. 18.2%, p< 0.001), stage 2 (28.3% vs. 24.0%, p= 0.023) but
38 39	202	not stage 3 (39.1% vs. 38.3%, p= 0.861) (Fig.3).
40 41	203	We conducted a check on the goodness of fit of the model and found that $p <$
42 43	204	0.05, indicates a good fit of the model. We also investigated the in-hospital and 180-
44 45	205	day survival in critical patients with AKI. The DEX group had significantly higher
46 47	206	freedom from death at in-hospital (86.5 vs. 82.4%, $p < 0.001$) and 180-day (78.0 vs.
48 49	207	72.8%, $p < 0.001$) than the non-DEX group, respectively (Fig.4).
50 51	208	Overall, the use of DEX had a significant beneficial effect on the in-hospital
52 53	209	mortality and 180-day mortality of AKI in critically ill patients.
54 55	210	Subgroup analysis
56 57	211	Subgroup analysis indicated that DEX use reduced in-hospital mortality of
58 59	212	critically ill patients with AKI (Supplementary Figure 1). There were no interactions
60	213	between age, gender, sepsis, AKI stage, and DEX use, suggesting that these results were

$\frac{1}{100} \text{ m patients with AKI (IIK. 0.02, \frac{35}{0} \text{ CI. } 0.55\text{-}0.70) \text{ during}$
over, Cox proportional hazards regression (HR: 0.61, 95% CI:
plementary table 1) and binary logistic regression (OR: 0.64, 95%
ementary table 2) were consistent with the trend of PSM modeling.
in in-hospital mortality was observed among critically ill patients
stage 1 (15.6% vs. 10.7%, p< 0.001), stage 2 (18.5% vs. 14.7%,
e 3 (27.6% vs. 26.6%, p= 0.848) (Fig.3).
DEX use also reduced 180-day mortality risk by 22% among
with AKI (HR: 0.77, 95% CI: 0.69-0.85) during PSM modeling.
rtional hazards regression (HR: 0.68, 95% CI: 0.63-0.74) (Fig.2,
3) and binary logistic regression (OR: 0.64, 95% CI: 0.57-0.71)
4) were consistent with the trend of PSM modeling. A significant
ortality was observed among critically ill patients receiving DEX
‰ vs. 18.2%, p< 0.001), stage 2 (28.3% vs. 24.0%, p= 0.023) but
38.3%, p= 0.861) (Fig.3).
check on the goodness of fit of the model and found that p<
fit of the model. We also investigated the in-hospital and 180-
patients with AKI. The DEX group had significantly higher
in-hospital (86.5 vs. 82.4%, p < 0.001) and 180-day (78.0 vs.
n the non-DEX group, respectively (Fig.4).
of DEX had a significant beneficial effect on the in-hospital
mortality of AKI in critically ill patients.
sis indicated that DEX use reduced in-hospital mortality of

and DEX use, suggesting that these results were

214 comparable for all populations.

215 Discussion

The present study showed that DEX use in severely ill AKI patients was linked with lower risk-adjusted in-hospital mortality and 180-day mortality. Consistent results were observed in different models. During subgroup analysis, after stratification according to age, gender, AKI stage, and sepsis, a strong correlation was still observed. Overall, we provide preliminary evidence that DEX has a beneficial effect on the prognosis of AKI in critically ill patients, providing the foothold to improve the outcomes of this patient population.

Overwhelming literature substantiates that DEX can alleviate AKI caused by several factors. Wang et al. previously uncovered that DEX could ameliorate AKI in mice with sepsis by partially inhibiting oxidative stress and apoptosis by modulating the p75NTR/p38MAPK/JNK signaling pathways.²⁵ Zhao et al. further substantiated that DEX protected against lipopolysaccharide-induced AKI by promoting autophagy mediated by PI3K/AKI/mTOR pathway inhibition.²⁶ A meta-analysis by Loomba et al. demonstrated that DEX could confer postoperative renal protective effects with lower NGAL levels and increased creatine clearance in patients who received DEX. These effects correlated with reduced ICU length of stay and risk of AKI and mortality.²⁷ Shan et al. found that DEX could minimize AKI incidence in Stanford type B aortic dissection (TBAD) patients after endovascular aortic repair (EVAR).²⁸ A single-center RCT of 108 patients²⁹ showed that prior administration of DEX within 24 hours after induction of anesthesia could reduce the incidence of AKI after aortic surgery under cardiopulmonary bypass. An RCT by Tang et al.³⁰ showed that DEX pretreatment attenuated AKI in patients. Animal studies further indicated that DEX could reduce cellular injury, improve renal function, and mitigate apoptosis in renal cells. Furthermore, Liu et al. revealed that DEX infusion in ICU patients with septic shock was linked to decreased AKI incidence and reduced ICU stay and CRRT performance. It is highly conceivable that the mechanism is related to anti-inflammatory effects and immunomodulation.³¹

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Inflammation is key to AKI pathogenesis, progression, and prognosis. An

 Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

increasing body of evidence suggests that DEX confers renoprotective effects and may be involved in the regulation of inflammation.³²⁻³⁴ A meta-analysis by Ma et al.³⁵ that included 4842 patients showed that DEX decreased pro-inflammatory like cytokines interleukin-6, C-reactive, tumor necrosis factor- α , and increased anti-inflammatory cytokines like IL-10 in surgical patients. A sub-analysis of a multicenter RCT by Ohta et al.³⁶ suggested that sedation using DEX reduced inflammation in patients with sepsis requiring mechanical ventilation. Animal studies have shown that DEX may have a protective effect on cisplatin-induced AKI, and its potential mechanism may be related to the regulation of apoptosis and inflammatory response.³⁷ In addition, DEX can ameliorate microcirculation disorders by decreasing norepinephrine levels in the blood and increasing urine output and renal blood flow.³⁸ Since our study did not collect inflammatory indicators, the hypothesis that DEX may attenuate excessive inflammation could not be confirmed, emphasizing the need for future studies. Emerging evidence substantiates the benefits of DEX in AKI, but the prognosis and follow-up of AKI in critically ill patients have been largely understudied. In the present study, we consistently found that the in-hospital mortality of AKI patients in the DEX group was significantly lower than in the non-DEX group. At the same time, we found that the 180-day mortality of AKI patients was consistent with the in-hospital mortality, suggesting that DEX use is associated with survival benefits in this particular patient population. Our research provides a theoretical basis for clinicians to use DEX to manage critically ill patients with AKI. In our research results, we also found that propofol reduced the risk of in-hospital mortality and 180-day mortality, and we speculate that this may be due to the renal protective effect of $propofol^{39-40}$.

Our subgroup analysis showed that DEX was effective in sepsis-associated-AKI (SA-AKI) patients, consistent with the literature.²¹ Consistently, Hu et al. analyzed 269 2192 patients with SA-AKI and found that DEX use was related to decreased inhospital mortality and improved renal function recovery of SA-AKI in critically ill 271 patients. Unlike Hu's study is that our study included all types of AKI populations in 272 the ICU. Our results showed that DEX use reduced in-hospital mortality of AKI in 273 critically ill patients. Follow-up analysis showed that DEX use reduced the 180-day Page 13 of 43

BMJ Open

mortality of patients. Our findings suggest DEX is effective against sepsis-associated AKI and for AKI patients in general and improves the long-term prognosis. The role of DEX on more types of AKI subgroups warrants further exploration in severely ill subjects. Our study found that using DEX in critically ill patients with AKI can reduce in-hospital mortality and 180-day mortality. Shehabi et al.^[41] found that early use of DEX sedation can reduce the 90-day mortality in elderly patients with critically ill mechanical ventilation in the SPICE III trial, whether the patient has surgery or not. On the contrary, a higher likelihood of an increase in 90-day mortality was observed in younger patients of non-surgical status. However, it has not been thoroughly researched for the use of DEX sedation in critically ill patients with AKI, and this study can serve as a supplement to such patients in the SPICE III trial.

Our research has several limitations. First, data acquired from this database was adopted to maximize generalizability and power. Accordingly, there was no formal calculation of sample size in this study. Although the sample size of the subgroup was comparatively larger compared to previous studies, it may also increase the risk of false positive results during multiple subgroup analyses. Second, our study's retrospective nature may have limited our findings' accuracy, and there could be other unknown potentially confounding factors that we were unable to control for. Third, we adjusted for many confounding factors, and PSM was conducted. Moreover, data analyzed in this study were acquired from a single-center observation database, emphasizing the need for a multicenter RCT to increase the robustness of our findings. Forth, due to the lack of admission diagnosis recorded in the MIMIC database, it is difficult for us to accurately identify the etiology of AKI in each patient. Therefore, the AKI patients defined in this study are actually unselected AKI. Although it is difficult to determine the exact cause of AKI and the reason why patients are admitted to the ICU, we have made necessary adjustments for other confounding factors that affect patient mortality. Our conclusion is stable and reliable, and may only apply to unselected AKI in critically ill patients. Fifth, This study did not consider the dosage and duration of DEX use, and further attention is needed in future studies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

303 Conclusion

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

5 305 6 307 8 306 9 307 11 308 12 308 13 309 14 309 15 310 17 311 19 312 21 313 23 314 25 315 26 315 27 316 29 317 31 318 32 319 34 320 37 321 38 322 40 323 41 323 42 324 43 324 44 325 46 327 50 328 52 329 51 328 52 329 54 321 35 322 40 323 42 324 43<	3	304
6 305 7 306 9 307 11 308 13 309 14 309 15 310 17 311 19 312 21 313 23 314 24 25 27 316 29 317 31 318 32 314 24 25 27 316 29 317 31 318 32 320 37 321 39 322 40 323 41 323 42 324 45 325 46 327 50 328 52 329 54 320 55 330 56 331 58 332	4 5	
8 306 9 307 11 308 13 309 14 309 15 310 17 311 19 312 21 313 22 313 23 314 24 314 25 315 26 317 31 318 32 319 34 320 37 321 38 320 36 321 39 322 40 323 41 323 42 324 43 324 44 325 46 327 50 328 52 329 51 328 52 329 54 320 55 330 56 331 58 329 54 329 5	6	305
10 307 11 308 13 309 15 310 17 311 19 312 21 313 22 313 23 314 25 315 26 31 27 316 29 317 31 318 32 319 34 320 35 320 36 321 39 322 40 323 41 323 42 324 43 324 44 323 45 325 46 323 47 326 48 327 50 328 52 329 53 329 54 330 55 330 56 331 58 332	8	306
12 308 13 309 14 309 15 310 17 311 19 312 21 313 23 314 24 315 27 316 29 317 31 318 32 321 33 319 34 320 37 321 38 320 37 321 38 320 37 321 38 320 37 321 38 320 37 321 38 320 37 321 38 322 40 41 43 324 44 325 46 327 50 328 52 329 53 329 54 330 55 331		307
13 309 14 310 15 310 17 311 19 312 21 313 22 313 23 314 24 315 26 315 27 316 29 317 31 318 32 320 37 321 38 320 36 321 39 322 40 323 41 323 42 324 43 324 44 325 46 326 47 326 48 327 50 328 52 329 51 328 52 329 53 329 54 330 55 330 56 331 58 332 59 332 <td></td> <td>308</td>		308
15 310 17 311 19 312 21 313 22 313 23 314 24 315 26 315 26 317 31 318 32 311 31 318 32 320 35 320 36 321 38 322 40 323 41 323 42 324 43 324 44 325 46 326 47 326 48 327 50 328 52 329 53 329 54 330 55 330 56 331 58 332 59 332	13	309
173111831220312213132231323314253152631273162931731318323193432036321393224032341323423244332444325463275032852329543305533156331583325933259332	15	310
19 312 21 313 22 314 24 314 25 315 26 317 30 31 31 318 32 320 36 321 39 322 40 323 41 323 42 324 43 324 44 325 46 325 46 326 47 326 48 327 50 328 52 329 53 329 54 330 55 330 56 331 57 331 58 332 59 332	17	311
21 313 22 314 25 315 26 315 27 316 29 317 30 31 31 318 32 320 36 321 38 322 40 323 41 323 42 324 43 324 44 325 46 326 47 326 48 327 50 328 52 329 53 329 54 330 55 330 56 331 58 332 59 332	19	312
22 23 314 24 315 25 315 27 316 29 317 30 31 31 318 32 320 36 320 37 321 38 322 40 323 42 324 43 324 44 325 46 325 46 326 47 326 48 327 50 328 52 329 53 329 54 330 55 331 56 331 58 332 59 332	21	313
24 25 315 26 315 27 316 29 317 30 31 31 318 32 320 36 321 39 322 40 323 41 323 42 324 43 324 44 325 46 325 46 327 50 328 52 329 53 329 54 330 56 331 57 331 58 332	22 23	
26 27 316 29 317 30 31 318 32 33 319 34 35 320 36 37 321 38 39 322 40 41 323 42 43 324 44 45 325 46 47 326 48 49 327 50 50 328 52 52 329 53 54 330 56 56 331 58 57 332 59 58 332 59	24	
28 317 30 317 31 318 32 319 34 320 35 320 36 37 37 321 38 322 40 41 41 323 42 324 43 324 44 325 46 326 47 326 48 327 50 328 52 329 53 329 54 330 55 331 56 331 58 332 59 332	26	
30 31 318 32 319 33 319 34 320 36 321 37 321 38 322 40 323 41 323 42 324 43 324 44 325 46 326 47 326 48 327 50 328 52 329 54 330 55 330 56 331 58 332 60 328	28	
32 33 319 34 35 320 36 37 321 38 39 322 40 41 323 42 43 324 43 324 44 325 46 325 46 327 50 328 51 328 52 329 54 330 56 331 58 332 60 328		317
33 319 34 35 320 36 37 321 38 39 322 40 41 323 41 323 42 324 43 324 44 45 325 46 326 47 326 48 327 50 328 52 329 53 329 54 330 56 331 58 332 60 328		318
35 320 36 37 321 38 39 322 40 41 323 41 323 324 43 324 324 44 325 46 47 326 327 50 328 52 51 328 52 52 329 53 54 330 55 56 331 58 58 332 60	33	319
37 321 38 322 40 323 41 323 42 324 43 324 44 325 46 326 48 327 50 328 52 329 53 329 54 330 56 331 58 332 60 328	35	320
39 322 40 323 41 323 42 324 43 324 44 325 46 326 47 326 48 327 50 328 51 328 52 329 54 330 56 331 58 332 60 328	37	321
41 323 42 324 43 324 44 325 46 326 47 326 48 327 50 328 52 329 53 329 54 330 56 331 58 332 60 328		322
43 324 44 325 46 326 47 326 48 327 50 328 51 328 52 329 54 330 56 331 58 332 59 60		323
45 325 46 326 47 326 48 327 50 328 51 328 52 329 53 329 54 330 56 331 58 332 59 60		324
47 326 48 327 50 328 51 328 52 329 53 329 54 330 56 331 58 332 59 60		325
49 327 50 328 51 328 52 329 53 329 54 330 56 331 57 58 59 60		326
50 328 51 329 53 329 54 330 55 331 57 58 59 60		327
52 329 53 330 54 330 56 331 57 332 58 332 59 60	50	328
54 330 55 331 57 332 58 332 59 60	52	329
56 331 57 58 332 59 60 60	54	330
58 332 59	56	331
60	58	332
		333

1 2

> This retrospective cohort study showed that dexmedetomidine administration significantly reduces risk-adjusted in-hospital and 180-day mortality in critically ill patients with AKI. However, further RCTs are needed to develop the robustness of our findings.

309 Acknowledgements We would like to thank the participants, patient advisers,

310 developers and investigators associated with the Medical Information Mart for

311 Intensive Care (MIMIC)-IV database.

- 312 **Contributors** WW and JL designed the study. YJ and PZ conducted data collection.
- 313 PG and HW conducted data analysis. WW wrote the manuscript. WW and JL
- analyzed and interpreted the result. All authors reviewed this manuscript.
- **Funding** This study was supported by The National Natural Science Fundation of
- 316 China (grant number: 81960669) and The National High Level Hospital Clinical
- 317 Research Funding (grant number: 2022-GSP-GG-22).
- 318 **Competing interests** None declared.
 - 319 **Patient and public involvement** Patients and/or the public were not involved in the
 - 320 design, or conduct, or reporting, or dissemination plans of this research.
 - 321 **Data availability statement** Data are available upon reasonable request.
 - 323 Reference:
 - 324 [1] Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global
 - 325 concern. Lancet 2013; 382: 170–179. doi:10.1016/S0140-6736(13)60647-9
- 326 [2] Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in
- 327 critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41:
- 328 1411-1423. doi:10.1007/s00134-015-3934-7
- 329 [3] Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk
- 330 stratification, and outcomes. Kidney Int 2012; 81: 819–25. doi:10.1038/ki.2011.339
- 331 [4] Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core
- 332 curriculum 2018. Am J Kidney Dis 2018; 72: 136–48.doi:10.1053/j.ajkd.2017.11.021
- 333 [5] Altshuler J, Spoelhof B. Pain, agitation, delirium, and neuromuscular blockade: a

Page 15 of 43

1

BMJ Open

1 2		
3 4	334	review of basic pharmacology, assessment, and monitoring. Crit Care Nurs Q
5 6	335	2013;36: 356-69.doi:10.1097/CNQ.0b013e3182a10dbf
7 8	336	[6] Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J
9 10	337	Anaesthesiol 2011;28: 3-6.doi:10.1097/EJA.0b013e32833e266d
11 12	338	[7] Møller MH, Alhazzani W, Lewis K, et al. Use of dexmedetomidine for sedation in
13 14	339	mechanically ventilated adult ICU patients: a rapid practice guideline. Intensive Care
15 16	340	Med 2022; 48(7): 801-810. doi:10.1007/s00134-022-06660-x
17 18	341	[8] Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more
19 20	342	than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive
21 22	343	Care Med 2004; 30: 2188-2196.doi:10.1007/s00134-004-2417-z
23 24	344	[9] Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress,
25 26	345	inflammation, and immune function: systematic review and meta-analysis. Br J
27 28	346	Anaesth 2019; 123: 777-94.doi:10.1016/j.bja.2019.07.027
29 30	347	[10] Shan XS, Dai HR, Zhao D, et al. Dexmedetomidine reduces acute kidney injury
31 32	348	after endovascular aortic repair of Stanford type B aortic dissection: A randomized,
33 34	349	double-blind, placebo-controlled pilot study. J Clin Anesth 2021; 75: 110498.
35 36	350	doi:10.1016/j.jclinane.2021.110498
37	351	[11] Zhai M, Kang F, Han M, et al. The effect of dexmedetomidine on renal function
38 39	352	in patients undergoing cardiac valve replacement under cardiopulmonary bypass: A
40 41	353	double-blind randomized controlled trial. J Clin Anesth 2017; 40:33-38.
42 43	354	doi:10.1016/j.jclinane.2017.03.053
44 45	355	[12] Zhao Y, Feng X, Li B, et al. Dexmedetomidine Protects Against
46 47	356	Lipopolysaccharide-Induced Acute Kidney Injury by Enhancing Autophagy Through
48 49	357	Inhibition of the PI3K/AKT/mTOR Pathway. Front Pharmacol 2020; 11: 128.
50 51	358	doi:10.3389/fphar.2020.00128
52 53	359	[13] Loomba RS, Villarreal EG, Dhargalkar J, et al. The effect of dexmedetomidine
54 55	360	on renal function after surgery: A systematic review and meta-analysis. J Clin Pharm
56 57	361	Ther 2022; 47(3): 287-297. doi:10.1111/jcpt.13527
58 59	362	[14] Johnson A, Bulgarelli L, Pollard T, et al. MIMIC-IV (version 2.0). PhysioNet
60	363	2022. Available from: https://doi.org/10.13026/7vcr-e114.

Page 16 of 43

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

2 3		
4	364	[15] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
5 6	365	Observational Studies in Epidemiology (STROBE) Statement: guidelines for
7 8	366	reporting observational studies. Int J Surg 2014; 12: 1495-
9 10	367	1499.doi:10.1016/j.ijsu.2014.07.013
11 12	368	[16] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron
13 14	369	Clin Pract 2012; 120: c179-84. doi:10.1159/000339789
15 16	370	[17] De Rosa S, Samoni S, Ronco C. Creatinine-based definitions: from baseline
17 18	371	creatinine to serum creatinine adjustment in intensive care. Crit Care 2016; 20: 69.
19 20	372	doi:10.1186/s13054-016-1218-4
21 22	373	[18]Vincent J-L, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess
23 24	374	the incidence of organ dysfunction/failure in intensive care units: results of a
25 26	375	multicenter, prospective study. Crit Care Med 1998; 26: 1793-800.
27 28	376	doi:10.1097/00003246-199811000-00016
29 30	377	[19] Sánchez-Díaz JS, Escarraman-Martínez D, Guerrero-Gutiérrez MA, et al.
31 32	378	Simplified acute physiology score II and Mannheim peritonitis index are associated
32 33 34	379	with in-hospital mortality in patients with abdominal sepsis admitted to ICU.
35	380	Simplified acute physiology score II y Mannheim peritonitis index se asocian a
36 37	381	mortalidad intrahospitalaria en pacientes con sepsis abdominal ingresados a la UCI.
38 39	382	Cir Cir 2022; 90: 81-91. doi:10.24875/CIRU.22000219
40 41	383	[20] Tao L, Zhou S, Chang P, et al. Effects of ondansetron use on outcomes of acute
42 43	384	kidney injury in critically ill patients: An analysis based on the MIMIC-IV database. J
44 45	385	Crit Care 2021; 66: 117-122. doi:10.1016/j.jcrc.2021.07.015
46 47	386	[21] Hu H, An S, Sha T, et al. Association between dexmedetomidine administration
48 49	387	and outcomes in critically ill patients with sepsis-associated acute kidney injury. J
50 51	388	Clin Anesth 2022; 83: 110960. doi:10.1016/j.jclinane.2022.110960
52 53	389	[22] Singer M, Deutschman CS, Seymour CW, et al. The Third International
54 55	390	Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (8):
56 57	391	801-810. doi:10.1001/jama.2016.0287
58 59	392	[23] Zhang Z, Xu X, Ni H, et al. Urine output on ICU entry is associated with hospital
60	393	mortality in unselected critically ill patients. J Nephrol 2014;27 (1):65-71.


2		
3 4	394	doi:10.1007/s40620-013-0024-1
5 6	395	[24] Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the
7 8	396	assessment of measured covariate balance to test causal associations in psychological
9 10	397	research. Psychol Methods 2010; 15 (3): 234-249. doi:10.1037/a0019623
11 12	398	[25] Wang Z, Wu J, Hu Z, et al. Dexmedetomidine Alleviates Lipopolysaccharide-
13 14	399	Induced Acute Kidney Injury by Inhibiting p75NTR-Mediated Oxidative Stress and
15 16	400	Apoptosis. Oxid Med Cell Longev 2020; 2020: 5454210. doi:10.1155/2020/5454210
17 18	401	[26] Zhao Y, Feng X, Li B, et al. Dexmedetomidine Protects Against
19 20	402	Lipopolysaccharide-Induced Acute Kidney Injury by Enhancing Autophagy Through
21 22	403	Inhibition of the PI3K/AKT/mTOR Pathway. Front Pharmacol 2020; 11: 128.
23 24	404	doi:10.3389/fphar.2020.00128
25 26	405	[27] Loomba RS, Villarreal EG, Dhargalkar J, et al. The effect of dexmedetomidine
20 27 28	406	on renal function after surgery: A systematic review and meta-analysis. J Clin Pharm
29	407	Ther 2022; 47: 287-297. doi:10.1111/jcpt.13527
30 31	408	[28] Shan XS, Dai HR, Zhao D, et al. Dexmedetomidine reduces acute kidney injury
32 33	409	after endovascular aortic repair of Stanford type B aortic dissection: A randomized,
34 35	410	double-blind, placebo-controlled pilot study. J Clin Anesth 2021; 75: 110498.
36 37	411	doi:10.1016/j.jclinane.2021.110498
38 39	412	[29] Soh S, Shim JK, Song JW, et al. Effect of dexmedetomidine on acute kidney
40 41	413	injury after aortic surgery: a single-centre, placebo-controlled, randomised controlled
42 43	414	trial. Br J Anaesth 2020; S0007-0912 (20) 30001-5.doi:10.1016/j.bja.2019.12.036
44 45	415	[30] Tang C, Hu Y, Gao J, et al. Dexmedetomidine pretreatment attenuates
46 47	416	myocardial ischemia reperfusion induced acute kidney injury and endoplasmic
48 49	417	reticulum stress in human and rat. Life Sci 2020; 257: 118004.
50 51	418	doi:10.1016/j.lfs.2020.118004
52 53	419	[31] Liu J, Shi K, Hong J, et al. Dexmedetomidine protects against acute kidney
54 55	420	injury in patients with septic shock. Ann Palliat Med 2020; 9: 224-230.
56 57	421	doi:10.21037/apm.2020.02.08
58 59	422	[32] Zhang J, Bi J, Ren Y, et al. Involvement of GPX4 in irisin's protection against
60	423	ischemia reperfusion-induced acute kidney injury. J Cell Physiol 2021; 236: 931-945.

1 2		
3 4	424	doi:10.1002/jcp.29903
5 6	425	[33] Zhao M, Wang Y, Li L, et al. Mitochondrial ROS promote mitochondrial
7 8	426	dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-
9 10	427	mediated mtDNA maintenance. Theranostics 2021; 11: 1845-1863.
11 12	428	doi:10.7150/thno.50905
13 14	429	[34] Hasegawa S, Inoue T, Nakamura Y, et al. Activation of Sympathetic Signaling in
15 16	430	Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-
17 18	431	Reperfusion Injury. J Am Soc Nephrol 2021; 32, 1599–1615.
19 20	432	doi:10.1681/ASN.2020121723
21 22	433	[35] Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress,
23 24	434	inflammation, and immune function: systematic review and meta-analysis. Br J
25 26	435	Anaesth 2019; 123: 777-794. doi:10.1016/j.bja.2019.07.027
27 28	436	[36] Ohta Y, Miyamoto K, Kawazoe Y, et al. Effect of dexmedetomidine on
29 30	437	inflammation in patients with sepsis requiring mechanical ventilation: a sub-analysis
31 32	438	of a multicenter randomized clinical trial. Crit Care 2020; 24: 493.
33	439	doi:10.1186/s13054-020-03207-8
34 35 26	440	[37] Liang H, Liu HZ, Wang HB, et al. Dexmedetomidine protects against cisplatin-
36 37	441	induced acute kidney injury in mice through regulating apoptosis and inflammation.
38 39	442	Inflamm Res 2017; 66: 399-411. doi:10.1007/s00011-017-1023-9
40 41	443	[38] Ebert Thomas J, Hall Judith E, Barney Jill A, et al. The effects of increasing
42 43	444	plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93:
44 45	445	382–94. doi:10.1097/00000542-200008000-00016
46 47	446	[39] Song Y, Paik HC, Kim N, et al. Effect of Propofol versus Sevoflurane Anesthesia
48 49	447	on Acute Kidney Injury after Lung Transplantation Surgery: A Prospective
50 51	448	Randomized Controlled Trial. J Clin Med 2022; 11 (22): 6862.
52 53	449	[40] Leite TT, Macedo E, Martins Ida S, et al. Renal Outcomes in Critically Ill
54 55	450	Patients Receiving Propofol or Midazolam. Clin J Am Soc Nephrol 2015; 10 (11):
56 57	451	1937-1945. doi:10.2215/CJN.02330315
58 59	452	[41] Shehabi Y, Serpa Neto A, Howe BD, et al. Early sedation with dexmedetomidine
60	453	in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE

BMJ Open

2		
3 4	454	III randomised controlled trial. Intensive Care Med 2021; 47 (4): 455-466
5 6	455	doi:10.1007/s00134-021-06356-8
7 8	456	
9 10	457	
11 12	458	
13	459	Figure Legends:
14 15	460	Fig.1. Flowchart of patients selection for the study. MIMIC-IV: Medical Information Mart for
16 17	461	Intensive Care Database IV; ICU: intensive care unit.
18 19	462	Fig.2. Association between in-hospital mortality, 180-day mortality and dexmedetomidine use of
20 21	463	AKI patients evaluated by the Cox model. HR, hazard ratio; CI: confidence interval; Unadjusted:
22 23	464	without adjustment; Multivarable adjusted: adjusted for all the baseline variables shown in Table 1.
24 25	465	PSM: propensity score matching.
26 27	466	Fig.3. In-hospital mortality and 180-day mortality of AKI in critically ill patients between the
28 29	467	dexmedetomidine and non-dexmedetomidine group in different AKI stage.
30 31	468 469	Fig.4. Freedom from death at in-hospital and 180-day in critically ill patients with AKI between the two groups.
32 33	470	Supplementary figure 1. Subgroup analysis of the association between dexmedetomidine use and
34 35	471	in-hospital mortality.
36 37		in-hospital mortality.
38 39		
40		
41 42		
43 44		
45		
46 47		
48 49		
49 50		
51 52		
53		
54 55		
55 56		
57		
58 59		
60		





For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml






Fig.2. Association between in-hospital mortality, 180-day mortality and dexmedetomidine use of AKI patients evaluated by the Cox model. HR, hazard ratio; CI: confidence interval; Unadjusted: without adjustment; Multivarable adjusted: adjusted for all the baseline variables shown in Table 1. PSM: propensity score matching.

338x190mm (96 x 96 DPI)





Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Supplementary table 1.

Cox logistic regression analysis of in-hospital mortality (before PSM)

BMJ Open

	Univariable		Multivariable	
Variables	HR (95%CI)	<i>P</i> value	HR (95%CI)	<i>P</i> value
Need of support				
Vasopressors	2.636 (2.415, 2.877)	<0.001	1.394 (1.251, 1.553)	<0.001
MV	4.108 (3.782, 4.462)	<0.001	4.090 (3.710, 4.509)	<0.001
CRRT	1.863 (1.680, 2.065)	<0.001	0.845 (0.750, 0.952)	0.006
Comorbidities at ICU admission				
Congestive heart failure	1.151 (1.058, 1.251)	0.001	1.229 (1.125, 1.342)	<0.001
Cerebrovascular disease	1.437 (1.307, 1.581)	<0.001	1.547 [1.403, 1.705]	<0.001
Chronic pulmonary	1.056 (0.965, 1.155)	0.237		
Renal disease	1.101 (1.005, 1.206)	0.040	1.025 [0.928, 1.132]	0.629
Liver disease	1.651 (1.505, 1.812)	<0.001	1.120 (1.009, 1.244)	0.033
Diabetes	0.901 (0.825, 0.984)	<0.001	0.818 [0.746, 0.898]	<0.001
Severity of illness				
SOFA score	1.115 (1.105, 1.125)	<0.001	1.007 [0.993, 1.021]	0.350
SAPS II score	1.033 (1.031, 1.036)	<0.001	1.018 (1.015, 1.021)	<0.001
Sedative-analgesic medications				
Propofol	0.788 (0.725, 0857)	<0.001	0.465 (0.421, 0.513)	<0.001
Midazolam	1.680 (1.547, 1.823)	<0.001	0.838 (0.758, 0.928)	0.001
Fentanyl	1.724 (1.568, 1.895)	<0.001	1.309 (1.154, 1.486)	<0.001
AKI stage				
AKI stage 1	Ref		Ref	
AKI stage 2	1.142 (1.071, 1.217)	<0.001	1.044 (0.955, 1.142)	0.342
AKI stage 3	1.800 (1.646, 1.969)	<0.001	1.048 (0.928, 1.183)	0.453
Lactate (mmol/L)	1.314 (1.292, 1.337)	<0.001	1.224 (1.199, 1.250)	<0.001
Sepsis	1.871 (1.670, 2.096)	<0.001	1.574 (1.304, 1.901)	<0.001
Antibiotic	1.366 (1.191, 1.562)	<0.001	0.665 (0.533, 0.831)	<0.001



Glucocorticoid	0.719 (0.645, 0.801)	< 0.001	0.709 (0.635, 0.791)	<0.001
DEX	0.585 (0.526, 0.650)	< 0.001	0.610 (0.546, 0.680)	<0.001
	MV, Mechanical ventilation; Cl		nplified Acute Physiology Score; al replacement therapy; AKI, Acut	-
Binary logistic	c regression analysis of Univariable	in-hospital mor	rtality (before PSM) Multivariable	
Variables	OR (95%CI)	<i>P</i> value	OR (95%CI)	<i>P</i> value
Need of support	0			
Vasopressors	5.730 (5.151, 6.375)	<0.001	2.040 (1.766, 2.357)	<0.001
MV	6.194 (5.645, 6.796)	<0.001	5.022 (4.468, 5.644)	<0.001
CRRT	4.960 (4.367, 5.633)	<0.001	1.320 (1.106, 1.575)	0.002
Comorbidities at ICU admis	sion			
Congestive heart failure	1.186 (1.083, 1.299)	<0.001	1.294 (1.156, 1.448)	<0.001
Cerebrovascular disease	1.668 (1.500, 1.854)	<0.001	2.302 (2.029, 2.612)	<0.001
Chronic pulmonary	1.069 (0.969, 1.178)	0.182		
Renal disease	1.206 (1.092, 1.333)	<0.001	1.010 (0.890, 1.146)	0.881
Liver disease	2.612 (2.350, 2.905)	<0.001	1.442 (1.253, 1.659)	<0.001
Diabetes	0.886 (0.806, 0.975)	0.013	0.776 (0.691, 0.871)	<0.001
Severity of illness				
SOFA score	1.222 (1.209, 1.236)	<0.001	1.041 (1.021, 1.060)	<0.001
SAPS II score	1.054 (1.051, 1.057)	<0.001	1.029 (1.024, 1.033)	<0.001
Sedative-analgesic medication	ons			
Propofol	1.129 (1.032, 1.235)	0.008	0.462 (0.406, 0.526)	<0.001
Midazolam	2.938 (2.685, 3.215)	<0.001	1.062 (0.935, 1.206)	0.353
Fentanyl	2.914 (2.638, 3.218)	<0.001	1.499 (1.296, 1.734)	< 0.001
AKI stage				
AKI stage 1	Ref		Ref	
		0.004		

AKI stage 3	2.139 (1.873, 2.442)	<0.001	1.105 (0.937, 1.305)	0.236
Lactate (mmol/L)	1.496 (1.449, 1.545)	<0.001	1.258 (1.212, 1.305)	<0.001
Sepsis	3.145 (2.794, 3.539)	<0.001	1.878 (1.527, 2.310)	<0.001
Antibiotic	2.246 (1.949, 2.587)	< 0.001	0.723 (0.566, 0.923)	0.009
Glucocorticoid	0.961 (0.855, 1.080)	0.505		
DEX	0.852 (0.762, 0.953)	0.005	0.639 (0.556,0.734)	< 0.001

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Supplementary table <u>3</u>2.

Cox logistic regression analysis of 180-day mortality (before PSM)

	Univariable		Multivariable
Variables	HR (95%CI)	P value	HR (95%CI) P value
Need of support		L	1
Vasopressors	2.771 (2.579, 2.977)	<0.001	1.454 (1.331, 1.588) <0.001
MV	2.626 (2.474, 2.788)	< 0.001	2.565 (2.390, 2.752) <0.001
CRRT	2.554 (2.345, 2.783)	<0.001	0.995 (0.899, 1.101) 0.920
Comorbidities at ICU admission			
Congestive heart failure	1.318 (1.240, 1.400)	< 0.001	1.194 (1.120, 1.273) <0.001
Cerebrovascular disease	1.423 (1.324, 1.530)	<0.001	1.581 (1.469, 1.701) <0.001
Chronic pulmonary	1.129 (1.058, 1.204)	<0.001	1.104 (1.033, 1.180) 0.004
Renal disease	1.379 (1.293, 1.472)	<0.001	1.090 (1.017, 1.168) 0.015
Liver disease	1.881 (1.749, 2.022)	<0.001	1.249 (1.152, 1.355) <0.001
Diabetes	0.982 (0.922, 1.046)	0.580	
Severity of illness			
SOFA score	1.129 (1.121, 1.136)	< 0.001	1.013 (1.001, 1.024) 0.029
SAPS II score	1.039 (1.037, 1.041)	<0.001	1.025 (1.023, 1.028) <0.001

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Sedative-analgesic medication	ons			
Propofol	0.715 (0.674, 0.758)	<0.001	0.448 (0.418, 0.482)	<0.001
Midazolam	1.809 (1.703, 1.923)	<0.001	0.910 (0.841, 0.986)	0.021
Fentanyl	1.492 (1.404, 1.586)	<0.001	1.242 (1.140, 1.352)	< 0.001
AKI stage				
AKI stage 1	Ref		Ref	
AKI stage 2	1.142 (1.071, 1.217)	<0.001	1.076 (1.009, 1.148)	0.025
AKI stage 3	1.800 (1.646, 1.969)	<0.001	1.097 (0.999, 1.204)	0.051
Lactate (mmol/L)	1.250 (1.232, 1.268)	<0.001	1.155 (1.134, 1.176)	< 0.001
Sepsis	2.060 (1.915, 2.215)	<0.001	1.664 (1.478, 1.874)	< 0.001
Antibiotic	1.531 (1.404, 1.669)	<0.001	0.808 (0.703, 0.928)	0.003
Glucocorticoid	1.162 (1.079, 1.251)	<0.001	1.072 (0.994, 1.156)	0.071
DEX	0.693 (0.639, 0.751)	<0.001	0.683 (0.626,0.744)	< 0.001

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

N.C.N

Supplementary table 4.

Binary logistic regression analysis of 180-day mortality (before PSM)

	Univariable		Multivariable		
Variables	OR (95%CI)	<i>P</i> value	OR (95%CI)	<i>P</i> value	
Need of support					
Vasopressors	3.346 (3,028, 3.697)	<0.001	1.604 (1.407, 1.828)	<0.001	
MV	2.960 (2.744, 3.193)	<0.001	3.059 (2.777, 3.371)	<0.001	
CRRT	3.273 (2.896, 3.699)	<0.001	1.117 (0.954, 1.309)	0.170	
Comorbidities at ICU admission					
Congestive heart failure	1.416 (1.318, 1.523)	<0.001	1.284 (1.178, 1.401)	<0.001	
Cerebrovascular disease	1.504 (1.376, 1.643)	<0.001	1.926 (1.740, 2.131)	<0.001	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Chronic pulmonary	1.171 (1.084, 1.265)	<0.001	1.156 (1.057, 1.264)	0.002
Renal disease	1.511 (1.397, 1.635)	<0.001	1.114 (1.014, 1.225)	0.025
Liver disease	2.125 (1.936, 2.332)	<0.001	1.458 (1.298, 1.638)	<0.001
Diabetes	0.993 (0.922, 1.070)	0.860		
Severity of illness				
SOFA score	1.156 (1.145, 1.166)	<0.001	1.012 (0.997, 1.028)	<0.001
SAPS II score	1.052 (1.049, 1.054)	<0.001	1.039 (1.035, 1.043)	<0.001
Sedative-analgesic medications				
Propofol	0.663 (0.618, 0.711)	<0.001	0.335 (0.302, 0.371)	<0.001
Midazolam	2.017 (1.871, 2.173)	<0.001	1.020 (0.918, 1.133)	0.709
Fentanyl	1.563 (1.456, 1.678)	<0.001	1.346 (1.206, 1.501)	<0.001
AKI stage				
AKI stage 1	Ref		Ref	
AKI stage 2	1.170 (1.085, 1.261)	<0.001	1.116 (1.026, 1.215)	0.011
AKI stage 3	2.014 (1.797, 2.256)	<0.001	1.151 (1.007, 1.314)	0.039
Lactate (mmol/L)	1.349 (1.310, 1.389)	<0.001	1.173 (1.135, 1.213)	<0.001
Sepsis	2.293 (2.112, 2.489)	<0.001	1.790 (1.560, 2.053)	< 0.001
Antibiotic	1.630 (1.478, 1.797)	<0.001	0.827 (0.704, 0.971)	0.021
Glucocorticoid	1.236 (1.131, 1.352)	<0.001	1.244 (1.124, 1.376)	<0.001
DEX	0.662 (0.604, 0.726)	<0.001	0.636 (0.569,0.711)	<0.001

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Subgroup	No. of Patients		OR (95% CI)	P for interaction
Age				0.6
≥60	10953	⊢ ∎1	0.69 (0.60-0.78)	
<60	4801	⊢-∎ i	0.445 (0.36-0.55)	
Gender				0.57
Female	6756	⊢■→	0.61 (0.53-0.71)	
Male	8998	⊢_ ∎1	0.70 (0.59-0.83)	
AKI				0.69
Stage 1	8548	⊢− ■−−1	0.63 (0.53-0.74)	
Stage 2	5695	⊢	0.70 (0.58-0.85)	
Stage 3	1511	⊢	0.62 (0.47-0.81)	
Sepsis				0.35
Yes	10601	⊢∎⊸1	0.66 (0.59-0.74)	
No	5153	۱ ــــــــــــــــــــــــــــــــــــ	0.51 (0.34-0.77)	
<	-			er>
	Age ≥60 <60 Gender Female Male AKI Stage 1 Stage 2 Stage 3 Sepsis Yes No	Age ≥60 10953 <60	Age ≥60 10953 <60	Age ≥ 60 10953 $\leftarrow \rightarrow \rightarrow$ 0.69 (0.60-0.78) <60 4801 $\leftarrow \rightarrow \rightarrow$ 0.445 (0.36-0.55) Gender 0.61 (0.53-0.71) Male 8998 $\leftarrow \rightarrow \rightarrow$ 0.70 (0.59-0.83) AKI Stage 1 8548 $\leftarrow \rightarrow \rightarrow$ 0.63 (0.53-0.74) Stage 2 5695 $\leftarrow \rightarrow \rightarrow$ 0.70 (0.58-0.85) Stage 3 1511 $\leftarrow \rightarrow \rightarrow$ 0.62 (0.47-0.81) Sepsis 0.61 (0.53-0.74) No 5153 $\leftarrow \rightarrow \rightarrow$ 0.60 (0.59-0.74) 0.325 0.50.60.70.80.9 1 0.51 (0.34-0.77) 0.51 (0.34-0.77)

Supplementary figure 1. Subgroup analysis of the association between dexmedetomidine use and in-hospital mortality.

STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Page No
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	1
		(<i>b</i>) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(<i>a</i>) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(<i>b</i>) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	4
		(b) Describe any methods used to examine subgroups and interactions	4
		(c) Explain how missing data were addressed	5
		(d) If applicable, explain how loss to follow-up was addressed	
		(<i>e</i>) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	Yes
Descriptive data			6
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	6

BMJ Open

Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6
		(b) Report category boundaries when continuous variables were categorized	6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6
Discussion			
Key results	18	Summarise key results with reference to study objectives	7
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	9
		Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,	9
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	8.9
Other informati	ion		-
Funding	22	Give the source of funding and the role of the funders for the present study and, if	1
		applicable, for the original study on which the present article is based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

Dear Prof. Shivali Fulchand:

Thank you very much for providing us with the opportunity to revise our manuscript. The red part that has been revised according to your comments.

We are grateful to the editor and reviewers for their constructive comments and helpful suggestions. Responding to the critics, we have conducted additional analyses as requested. We also gave more detail about the methodology. We believe that our manuscript has been substantially improved and hope it is now acceptable for the BMJ Open.

I assure you that all authors have read and approved the submission of the revised manuscript. Also, this work containing the original research has not been published previously nor is under consideration for publication elsewhere.

Please let me know if you might have any further questions.

Jinping Liu

Department of Cardiopulmonary Bypass

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital

National Center for Cardiovascular Diseases

Chinese Academy of Medical Sciences and Peking Union Medical College No.167, North Lishi Road, Xicheng District, 100037, Beijing, China E-mail: liujinping@fuwai.com

Editor

Editor point 1: Please revise the 'Strengths and limitations of this study' section of your manuscript (after the abstract). This section should contain up to five short bullet points, no longer than one sentence each, that relate specifically to the methods. The novelty, aims, results or expected impact of the study should not be summarised here.

Author response 1: Thank you for your comments. We have made necessary modifications to 'Strengths and limitations of this study' section according to your suggestion (Lines 41-52).

Editor point 2: We have noticed that Tables embedded in the main document have more than 2 pages. Please be informed that we allow a maximum 2 pages for tables embedded in the main document therefore please can you amend your table in order to fit in the Journal's structured format for tables.

Author response 2: Thank you for your comments. We have made necessary changes to the table style according to your suggestion to ensure that readers can obtain the best viewing experience (Lines 207-211). Thank you again.

Reviewer

Reviewer: 1

Point 1: Abstract:

Define in-hospital mortality with a time-frame (e.g. 30 days?) or definition (any time within the same hospital stay as the original ICU admission?)

Author response 1: Thank you for your reminder this issue. In this study, two types of outcome events were defined, namely in-hospital mortality and 180-day mortality. In-hospital mortality refers to the death of a patient during this hospitalization, which was recorded by the hospital. In the MIMIC-IV database, this type of patients was marked with a "hospital expire flag" to indicate the hospital death during this hospitalization. If a patient has been hospitalized multiple times, we only select the patient's first check-in record. We have provided a more detailed explanation of the

outcome events, especially the in-hospital mortality in the resubmit manuscript (Lines 139-145). Thank you again.

Point 2: Strengths and limitations:

 'The conclusions are qualitative, not quantitative'. May need some expanding- it is not immediately clear what is meant by this, especially as quantitative results are provided.

Author response 2: Thank you for pointing out this issue. We agree with this suggestion and we have made modifications to the 'strengths and limitations' in the resubmit manuscript to appear more rigorous (Lines 41-52). Thank you again.

Point 3: Introduction

Please provide references to the previously-conducted research, which you mention towards the end of the final paragraph. I think you should be upfront about causal effect estimation, since that is what you are trying to achieve here via covariate adjustment.

Author response 3: Thank you for your reminder. We have attached the relevant references to the previous literature mentioned in the introduction section. At the same time, we have supplemented our research hypotheses and intentions based on your suggestions (Lines 74-80). Thank you very much for your careful guidance.

Point 4: Methods

Source of acute kidney injury/reason for admission to ICU is not reported, which could be significant (E.g. after surgery or sepsis).

Patients who were missing more than 5% of potential risk variables that are associated with mortality were excluded; what were these variables? I note you reference Zhao et al. (2020), who define a similar population, but it is not clear exactly which variables were used to identify this- was it only for missing covariates?

Table 1 should be in the results section.

Author response 4: Thank you for your reminder. This is indeed an issue that cannot be ignored. The etiology of AKI and the reason why patients are admitted to the ICU are important confounding factors. However, due to the lack of admission diagnosis

recorded in the MIMIC database, it is difficult for us to accurately identify the cause of AKI in each patient. Therefore, the AKI patients we defined in this study are actually 'unselected AKI'. Although it is difficult to determine the exact cause of AKI and the reason why patients are admitted to the ICU, we have made necessary adjustments for other confounding factors that affect patient mortality. Our conclusion is stable and reliable, but as you mentioned, our conclusion may only apply to 'unselected AKI'. We have provided additional clarification on this issue in the limitations section (Lines 323-329).

Patients who missed more than 5% of potential risk variables related to mortality were excluded from the study, which referred to the description of a similar population defined by Zhao et al. (2020), but was not specifically described in the references. Therefore, this sentence was deleted from our resubmitted manuscript (Lines 104-105).

At the same time, we reset Table 1 in the results section and made necessary formatting adjustments to the table (Lines 207-211). Thank you very much for your careful guidance.

Point 5: Covariates-defined based on reference 19 (Early administration of glucocorticoid for thyroid storm: analysis of a national administrative database; Senda et al., 2020)- it is not clear why you believe similar adjustment sets would apply here. Common causes of the exposure (DEX use) and outcome (mortality) should be adjusted for here, ideally informed via drawing out the hypothesised causal relationships using a directed acyclic graph.

Author response 5: Thank you for your reminder. When selecting covariates, we prioritize variables that are accurately related to outcome events. The determination of these variables is mainly based on clinical practice and previous literature. We realized that selecting this literature was not appropriate, so we replaced it with other literature that could better explain the selection of covariates (reference 20-21). At the same time, we also carefully considered the included covariates based on the actual situation of the MIMIC database (in fact, there are some important variables that we

 cannot obtain from the database, including the etiology of AKI and the reason for admission to the ICU you mentioned earlier) and the variables presented in this study were ultimately determined. We have revised our references to make readers aware of our covariate selection principles (Lines 116-118). Thank you again.

Point 6: Exposure: DEX use was defined as patients who received any dexmedetomidine treatment throughout hospitalization in the ICU, whatever the dosage. I'm not sure how much variability could be in the use of DEX. The target trial framework would have helped with defining the exposure. Would you expect to see differential effects between those with 1-2 exposures compared with extended periods of sedation- and what might be the variables that need to be adjusted for in this scenario (i.e. greater exposure to sedatives may be more unwell)?

Author response 6: Thank you for your reminder. Due to the complexity of dealing with the database dose (e.g. differences in DEX usage days and hard to homogenize), we finally consider whether to use DEX for patients as a categorical variable to explore its impact on the outcome. At the same time, we referred to the definition in reference [20] Tao (2021) et al. 'Effects of ondansetron use on outputs of acute kidney injury in critically ill patients: An analysis based on the MIMIC-IV database' for description. The dosage and duration of DEX use may indeed be potential factors affecting outcomes, and we supplemented this issue in the limitations section (Lines **329-330**). Thank you very much for pointing out this issue.

Point 7: Outcome: in-hospital mortality and 180-day mortality of AKI patients in the ICU. Is there any distinction between AKI mortality and all-cause mortality? I note in the objectives in the abstract, you refer to kidney-related mortality, but it is not clear whether that is the outcome ultimately used.

Author response 7: Thank you for your reminder. In fact, we can only trace the allcause death of the patient from the MIMIC database, and we cannot identify the kidney-related mortality. We have modified the corresponding expression in the objectives in the abstract. Thank you again (Lines 17-19).

Point 8: Statistical analysis: there is an error in the reference #20 (year published is

2010, not 2015). Please specify which covariates were included in the propensity score model. The propensity score approach itself seems reasonable, but I am concerned the model could be misspecified due to potential errors in defining the exposure, and no justification for confounder selection.

Author response 8: Thank you for your careful reminder. We are very sorry for our incorrect reference cite and we have corrected the incorrect reference. We indicate these variables in the covariates section of the revised manuscript. These variables are baseline characteristics of patients and are closely related to outcome events (specifically referring to the research of Tao et al in reference 20-21 and clinical practice). After balancing these variables, we believe that our outcomes will be more reliable and stable (Lines 421-426). We have also corrected our definition of exposure in the objectives section (Lines 17-19). Thank you very much for your careful guidance.

Point 9: Consider use of an alternate outcome model. Although Cox proportional hazards models are commonly used because covariate adjustment is relatively straightforward, they cannot give causal estimates (see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653612/). Also, if you are using all-cause mortality, you do not need to account for competing risks, but if you do conduct an analysis using kidney-related mortality only, you will need to consider the competing risk of all-cause mortality.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Author response 9: Thank you for your suggestion. We have carefully read the literature you recommended. Indeed, there are certain drawbacks to using Cox regression models for causal reasoning. The PSM analysis in this study is actually a method of adjusting observational data, which can reduce the impact of potential confounding variables between intervention factors and outcomes. According to your suggestion, we additionally performed binary logistic regression to better causal inference. Finally, we found that the use of DEX is still an independent risk factor for reducing mortality. We have supplemented the above results in the resubmit manuscript (**Supplementary table 2 and 4**). Thank you again.

Point 10: Results:

 Since you mention that DEX is guideline recommended, it is interesting that the treatment group- especially since it is comprised of any exposure to DEX over the period of interest Refer to statistically significant results as such (not just significant). Ensure results are summarised appropriately-for example include error bars on Figure 3.

Author response 10: The question you raised is very interesting, but in fact, the guide we mentioned was released in 2013, so we have updated the guide reference [7] (2022) (Lines 367-369). In order to minimize bias as much as possible, we also used statistical methods such as PSM and regression analysis to correct for possible confounding factors, which made the conclusions of this study (based on real-world data) more credible. Our Figure 3 references the drawing method of Tao et al. in reference [20]. Thank you for your thoughtful suggestions (Lines 421-423).

Point 11: Discussion

Seems reasonable based on results. Good discussion of previous findings. Ensure absolute risk discussed as well as relative risk.

Author response 11: Thank you for your affirmation and suggestion. We have made necessary modifications to this study based on your suggestions to ensure that the risks reported are true and reasonable. We once again express our gratitude to you. Your carefully suggestions and guidance have made the conclusions we have drawn more reliable and stable. Thank you very much.

Reviewer: 2

Point 1: Abstract:

"acute kidney injury (AKI)-associated mortality": This would be almost impossible to define from such database. It would assume the study analysed "all-cause mortality in patients with AKI at ICU admission".

Author response 1: Thank you for your reminder. We are very sorry for our incorrect writing. In fact, we can only trace the all-cause mortality of patients from the MIMIC

database and cannot identify kidney-related mortality. We have modified the corresponding wording in the objectives (Lines 17-19) and emphasized the limitations in the section (Lines 323-329). Thank you for your careful guidance.

Point 2: Introduction:

"Current guidelines recommend dexmedetomidine (DEX) for sedation in an intensive care setting." The cited reference is outdated, there are more recent guidelines for ICU sedation.

Author response 2: Thank you very much for your suggestion. We have carefully read the latest guide and referenced it [7] in the appropriate location (Lines 367-369). Thank you again.

Point 3: Methods:

«The primary outcome was in-hospital mortality and 180-day mortality of AKI patients in the ICU»: Were these co-primary outcomes? If not, one should be declared the primary outcome and the other one is a secondary outcome. Of note, in the abstract, in-hospital mortality is declared to be the primary and 180-day mortality a secondary outcome. This should be clarified.

Author response 3: Thank you for your suggestion. Indeed, there can usually only be one primary outcome. We have followed your suggestion to clearly define primary outcome as in-hospital mortality and secondary outcome as 180-day mortality (Lines 25-26) (Lines 144-145). Thank you for pointing out this issue.

Point 4: PSM analysis was performed, but most results presented for whole cohort. The authors should clearly indicate which results are from the PSM cohort and which are from the whole cohort. They should also justify their decision to report results for the whole cohort, especially if there are substantial differences between the whole cohort and the PSM cohort.

Author response 4: Thank you for your reminder. We have re described the results section according to your suggestion and provided a detailed explanation of the results before and after PSM. In fact, the variables we selected for inclusion in PSM are all baseline characteristics of patients and are closely related to outcome events. After

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

careful baseline balancing, the two groups of patients achieved 'post-hoc randomization', which simulated prospective RCT and made the results more reliable (Lines 173-197). Thank you very much.

Point 5: For PSM, "The choice of covariate was based on other relevant studies": The study cited is a retrospective cohort study of 811 patients on the effect of glucocorticoids on the survival of patients with thyroid storm that used a different statistical approach except for PSM. I respectfully disagree that this is the best approach to select the covariates.

Author response 5: Thank you for your reminder. The variables we selected were baseline characteristics of patients and were closely related to outcome events. When selecting covariates, the determination of these variables was mainly based on clinical practice and previous literature. We re-emphasized the basis for selecting covariates in the methodology section. Based on your suggestion, we realized that choosing this literature was not appropriate, so we have replaced it with other literature that can better explain covariate selection and we will no longer cite this literature in the resubmit manuscript (Lines 112-118). We are very sorry for our incorrect reference cite and thank you for your careful guidance.

Point 6: Results:

Even the unadjusted HR for death was highly significant in favor of DEX. This is very surprising, as no adjustment was made for time, dose and duration of DEX. This might point to selection bias of giving DEX to patients who are more stable and more likely to survive. This should be explained and addressed in the discussion.

Author response 6: Thank you for your reminder. Due to the complexity of dealing with the database dose (e.g. differences in DEX usage days and hard to homogenize), we finally consider whether to use DEX for patients as a categorical variable to explore its impact on the outcome. At the same time, we referred to the definition in reference [20] Tao (2021) et al. 'Effects of ondansetron use on outputs of acute kidney injury in critically ill patients: An analysis based on the MIMIC-IV database' for description (Lines 421-423). The dosage and duration of DEX use may indeed be

potential factors affecting outcomes, and we supplemented this issue in the limitations section (Lines 329-330). Thank you again.

Point 7: It looks like, in the Cox logistic regression analysis, propofol reduces the OR of death compared to no propofol-this is a very unexpected finding and hard to believe, and should be explained. The proportional hazards assumption should be checked and the authors should assess the risk of overfitting the model, e.g. include the number of events per variable. Finally, the authors could have reported the model's goodness of fit to facilitate the interpretation of the results.

Author response 7:

Thank you for your suggestion. We found in the literature that propofol has a renal protective effect. Therefore, we suspect that reducing the risk of in-hospital mortality and 180-day mortality may be through renal protection. We also added a discussion on the results of propofol in the discussion section of the resubmit manuscript (Lines 292-294).

As for the model's goodness of fit, we have fitted the Cox models of in-hospital mortality and 180-day mortality and found that both models were P<0.05, indicating good fit. We have also added the results to the resubmit manuscript. (Lines 231-232). Thank you for your careful guidance.

Point 8: The authors selected the potential risk variables that are associated with mortality from a study furosemide, not necessarily including AKI patients. The actual variables included in the model and the rationale to select them should be reported.

Author response 8: Thank you for your reminder. When selecting covariates, we prioritize variables that are accurately related to the outcome event. The determination of these variables is mainly based on clinical practice and previous literature. We have referred to other literature that can better explain the selection of covariates in our resubmitted manuscript (references 20-21) (Lines 421-426). We matched the baseline characteristics of patients and factors that can affect AKI, and AKI can increase patient mortality. Therefore, we also matched at the baseline. Thank you for pointing out this issue.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Point 9: The authors did not report any adjustments for multiple subgroup analyses, which increases the risk of a type-I error.

Author response 9: Thank you for your reminder. We have adjusted the variables for subgroup analysis, but missed the explanation in the manuscript. Therefore, we have provided additional explanations in the statistical analysis section of the resubmit manuscript (Lines 157-169). Thank you for your careful guidance.

Point 10: Table 1:

At baseline, propofol was given to 50% and 90% of patients in the non-Dex and DEX group. However only 23% and 33% of these patients received mechanical ventilation. This is very unusual if not implausible, as propofol is usually given to sedate ventilated patients. How exactly were the baseline variables defined? At ICU admission or within the first 24 hours? Differences in the exact definition of these variables are important and might influence the validity and interpretation of the statistical model.

Author response 10: Thank you for your reminder. Mechanical ventilation we included was based on the first day of ICU admission. Our baseline is also based on data from the first day of ICU admission, and whether to use propofol or other medications for treatment is record during the period of ICU admission, so these seemingly unreasonable results may appear. Therefore, we provide a detailed definition of the sources of these variables in the data definition section (Lines 127-136). Thank you for pointing out this issue.

Point 11: Figure 4

There must be an error with the numbers in the graph on the left in Fig 4: It looks like the majority of patients have died. Were the patients discharged alive counted as events rather than censored?

Author response 11: Thank you for your suggestion. We carefully examined our original data and we define the follow-up time for in-hospital mortality using the length of hospital stay, which is different from the 180-day mortality follow-up time. Therefore, there is a difference in the shape of the graphs produced by the two.

This is due to the specificity of the follow-up time for in-hospital mortality, but the trend of the results is consistent. There is a literature [23] that introduces the variable of in-hospital mortality (Hospital mortality was considered as a time-to-event variable. The event was death during hospitalization. A patient was censored when he or she was discharged alive. Patients were followed during their hospital stay.), so we cited it in the article. Thank you again for your reminder (Lines 140-141).

Point 12: Discussion:

Timing and dose of the intervention, type and duration of surgery, unmeasured patient characteristics, and perioperative therapeutic strategies are important confounders in this study, and this should be mentioned in the discussion. Moreover, the results should be put into perspective of the SPICE III trial and it's relevant post-hoc analyses.

Author response 12: Thank you for your reminder. Due to the complexity of dealing with the database dose (e.g. differences in DEX usage days and hard to homogenize), we finally consider whether to use DEX for patients as a categorical variable to explore its impact on the outcome. At the same time, we referred to the definition in reference [20] Tao (2021) et al. 'Effects of ondansetron use on outputs of acute kidney injury in critically ill patients: An analysis based on the MIMIC-IV database' for description (Lines 421-423). The dosage and duration of DEX use may indeed be potential factors affecting outcomes, and we supplemented this issue in the limitations section and we will continue to focus on this issue in our future research (Lines 329-330).

Our study found that using DEX in critically ill patients with AKI can reduce inhospital mortality and 180-day mortality. Shehabi et al [41] in a SPICE III trial found that early use of DEX sedation can reduce the 90-day mortality in elderly patients with critically ill mechanical ventilation, whatever the patient has surgery or not. On the contrary, a higher likelihood of an increase in 90-day mortality was observed in younger patients of non-surgical status. However, it has not been thoroughly research

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

BMJ Open

> for the use of DEX sedation in critically ill patients with AKI, and this study can serve as a supplement to such patients in the SPICE III trial. We also added a discussion in the resubmit manuscript (Lines 305-312). Thank you again for your careful guidance.

s in th. .es 305-312).

BMJ Open

The impact of dexmedetomidine on mortality in critically ill patients with acute kidney injury: A retrospective propensity score matching analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-073675.R2
Article Type:	Original research
Date Submitted by the Author:	12-Sep-2023
Complete List of Authors:	Wang, Wenting; Peking Union Medical College Jin, Yu; Peking Union Medical College Zhang, Peiyao; Peking Union Medical College Gao, Peng; Peking Union Medical College Wang, He; Peking Union Medical College, Department of Cardiopulmonary Bypass Liu, Jinping; Peking Union Medical College Hospital, Department of Cardiopulmonary Bypass
Primary Subject Heading :	Intensive care
Secondary Subject Heading:	Medical management, Renal medicine
Keywords:	INTENSIVE & CRITICAL CARE, Acute renal failure < NEPHROLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Page 2 of 31

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

2	
3	
4	
5	
6	
6 7	
8	
9	
10	
11 12	
12	
12 13 14 15	
14	
15	
16 17	
17	
18	
19	
20	
21	
22	
20 21 22 23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
43 44	
44 45	
45 46	
47 40	
48	
49 50	
50	
51 52	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1

1	The impact of dexmedetomidine on mortality in critically ill patients with
2	acute kidney injury: A retrospective propensity score matching analysis
3	
4	Authors: Wenting Wang ¹ , Yu Jin ¹ , Peiyao Zhang ¹ , Peng Gao ¹ , He Wang ¹ , Jinping
5	Liu ¹ *
6	
7	Institutions: ¹ Department of Cardiopulmonary Bypass, State Key Laboratory of
8	Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular
9	Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College,
10	Beijing, China
11	
12	Corresponding Author: Jinping Liu; Fuwai hospital, No.167, North Lishi Road,
13	Xicheng District, 100037, Beijing, China; E-mail: liujinping@fuwai.com; TEL: 010-
14	88396257, FAX: 010-88396257.
15	
16	Abstract:
17	Objectives This study sought to estimate the effect of dexmedetomidine (DEX)
18	administration on mortality in critically ill patients with acute kidney injury (AKI).
19	Design A retrospective cohort study.
20	Setting The study sourced its data from the Multiparameter Intelligent Monitoring in
21	Intensive Care Database IV (MIMIC-IV), a comprehensive database of ICU patients.
22	Participants A total of 15754 critically ill patients with AKI were enrolled from the
23	MIMIC-IV database.
24	Primary and secondary outcome Primary outcome was in-hospital mortality and
25	secondary outcome was 180-day mortality.
26	Results 15754 critically ill AKI patients were included in our analysis. We found that
27	DEX use decreased in-hospital mortality risk by 38% (HR: 0.62, 95% CI: 0.55-0.70)
28	and 180-day mortality risk by 23% (HR: 0.77, 95% CI: 0.69-0.85). After adjusting for
29	confounding factors, DEX can reduce all three stages of AKI in in-hospital mortality.

1	
2	
3 4	
4	
5	
6	
6 7	
8	
8 9	
10	
11	
12	
13	
12 13 14 15	
15	
16	
16 17	
18	
18 19	
20	
20	
20 21 22 23	
22	
23	
24	
25	
26	
ע∠ 27	
27	
28	
29	
30	
31	
32	
33	
34	
54 25	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
54 55	
56	
57	
58	
59	
60	

 with decreased risk-adjusted in-hospital and 180-day mortality in critically ill AKI patients. Nonetheless, future randomized controlled trials (RCTs) are warranted to validate our findings. Keywords: Dexmedetomidine, AKI, Mortality, MIMIC-IV, Propensity score matching Strengths and limitations of this study This study included 15754 patients, which is a very large sample size for a clinical study of critically ill patients with AKI.
 validate our findings. Keywords: Dexmedetomidine, AKI, Mortality, MIMIC-IV, Propensity score matching Strengths and limitations of this study This study included 15754 patients, which is a very large sample size for a
 Keywords: Dexmedetomidine, AKI, Mortality, MIMIC-IV, Propensity score matching Strengths and limitations of this study This study included 15754 patients, which is a very large sample size for a
 35 36 37 Strengths and limitations of this study 38 • This study included 15754 patients, which is a very large sample size for a
 36 37 Strengths and limitations of this study 38 • This study included 15754 patients, which is a very large sample size for a
 37 Strengths and limitations of this study 38 • This study included 15754 patients, which is a very large sample size for a
 37 Strengths and limitations of this study 38 • This study included 15754 patients, which is a very large sample size for a
• This study included 15754 patients, which is a very large sample size for a
39 clinical study of critically ill patients with AKI.
• Additional confounding factors were adjusted and increased the reliability of
41 our results and conducted a subgroup analysis of the association between DEX
42 use and in-hospital mortality.
• This retrospective study was unable to conduct long-term follow-up, so we
44 look forward to future multicenter clinical studies to make up for this
45 deficiency and further verify the stability of the results in this study.
• The data of this study was from a MIMIC-IV database, and some data may be
47 missing which slightly offsets the results.
47 missing which slightly offsets the results.48
49
50 Introduction
51 Over the past few decades, the prevalence of acute kidney injury (AKI) has
52 significantly increased and has gradually become a global health concern.[1] AKI is a
53 common comorbidity among severely ill patients that require intensive care. Indeed,
54 more than half of patients experience AKI during their stay in the intensive care unit
55 (ICU).[2] AKI is related to adverse outcomes, increases CKD occurrence and kidney
replacement therapy, and raises the risk of short- and long-term deaths,[3] causing huge

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

social and economic burdens to patients and society. However, further research iswarranted to optimize the management of AKI.[4]

In the context of critical care, effective sedation is of utmost importance for managing agitation and anxiety in patients.[5] The primary objective of sedation in the ICU is to achieve a state of calmness and cooperation in the patient, allowing for the easy awakening and clear communication of needs, particularly concerning pain management.[6] There is evidence to suggest that maintaining light sedation in patients in the ICU can lead to better outcomes. Current guidelines recommend dexmedetomidine (DEX) for sedation in an intensive care setting.[7] DEX is widely used in ICU as a highly selective alpha-2 agonist.[8] An increasing body of evidence suggests that DEX can inhibit the production of excess inflammation cytokine and protect renal function, which may positively impact the prognosis of AKI.[9-11]However, the renoprotective effects of DEX in critically ill patients have not been explored, based on the above characteristics of DEX, we assume that the use of DEX can reduce the mortality rate of AKI patients. The current literature consists mainly of basic-level studies or small samples of other population cohorts, with a paucity of largescale research.[12-13] Hence, the present study aims to investigate DEX's effect on AKI-related mortality in critically ill patients based on a large sample of critical care public databases.

76 Methods

77 Data sources

The study sourced its data from the Multiparameter Intelligent Monitoring in Intensive Care Database IV (MIMIC-IV), a comprehensive database of ICU patients.[14] We collected data on AKI patients from the MIMIC-IV database treated with or without DEX. This database contains a publicly available and real-world clinical database of patients at the Beth Israel Deaconess Medical Center from 2008 to 2019. Informed consent of patients was not required in this study since confidential patient information was already deleted. All reports followed the guidelines of Strengthening Epidemiological Observation and Research Report (STROBE).[15] A Collaborative Institutional Training Initiative (CITI) license (Certificate No. 11326088)

BMJ Open

was obtained by Wang W, who was entitled to extract data from the MIMIC-IVdatabase in accordance with the relevant regulations.

89 Participants

This study included patients who were admitted to the ICU and diagnosed with acute kidney injury (AKI) according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria.[16] The definition of baseline serum creatinine level (SCr) in this study was based on two criteria: 1) the minimum SCr level recorded within 7 days before ICU admission, or 2) if there was no SCr data available before admission, the first SCr level measured upon admission to the ICU was used as the baseline.[17] The MIMIC IV 2.0 database only contains data on adults older than 18. Patients who met any of the following criteria were excluded from the study: (1) death within 48 hours after admission to the ICU, (2) ICU stays less than 48 hours.

99 Covariates

The study included demographic characteristics and clinical characteristics with 24-hour average values. The Sequential Organ Failure Assessment (SOFA) score,[18] and Simplified Acute Physiology Score (SAPS) II,[19] were calculated within the first 24 h after the ICU admission. We collected the following clinical information of each patient: demographics, laboratory measurements, vital signs, ethnicity, admission type, need of support, comorbidities at ICU admission, severity of illness, sedative-analgesic medications use, AKI stage, sepsis, antibiotic use, glucocorticoid use(Table 1). These covariates, including clinical characteristics and basic demographic information, were based on other relevant studies and clinical practice.[20-22]

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

109 Data definitions

Extracted data from MIMIC-IV on the first day of ICU admission, including age, gender, laboratory measurements, vital signs, ethnicity, admission type, vasopressors, mechanical ventilation (MV), continuous renal replacement therapy (CRRT), comorbidities, SOFA score, SAPS II score. We also collected information on whether DEX, propofol, midazolam, fentanyl, antibiotics, and glucocorticoids were used during ICU hospitalization. Sepsis was defined as a life-threatening organ dysfunction caused by a dysregulation of host response to infection (Sepsis 3.0),[23] which refers to patients with documented or suspected infections and acute changes in the SOFA score
≥ 2 points.

DEX use was defined as patients who received any dexmedetomidine treatmentthroughout hospitalization in the ICU.

121 Outcomes

In-hospital mortality refers to the death of patients during this hospitalization, which was recorded by the hospital.[24] In the MIMIC-IV database, this type of patients will be marked with a 'hospital expire flag' to indicate the hospital death during this hospitalization. If a patient has been hospitalized multiple times, we only select the first check-in record. The primary outcome was in-hospital mortality and the second outcome was 180-day mortality of AKI patients in the ICU.

128 Statistical analysis

Our study presented continuous variables described as mean±standard deviaton for normally distributed or as the median and interguartile range (IQR) if not normally distributed, while the t-test or Mann-Whitney U test was utilized for comparison between groups, respectively. Categorical variables were presented using numbers and percentages (%), and the chi-square test or Fisher's exact test was adopted from group comparisons. We used propensity score matching (PSM) by 1:1 nearest neighbor matching to adjust the baseline difference between the groups. The caliper value was set to 0.2 between matching participants. The standardized mean difference (SMD) was calculated to determine the balance within the model (Table 1), and SMD greater than 0.1 was considered unbalanced.[25]

We used Cox proportional hazards regression and binary logistic regression to assess the effect of DEX use on in-hospital mortality and 180-day mortality. In the subgroup analysis, we used binary logistic regression analysis of in-hospital mortality to assess the effect of DEX use on in-hospital mortality in subgroup populations. Parameters with a p-value< 0.1 during univariate analysis and potential confounding factors were included in the multivariate regression model. In the subgroup analysis, we classified patients based on age, gender, AKI stage, and sepsis incidence to assess

1	
2	
3	
4	
5	
6	
7	
, 8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	C
47	
48	
49	
49 50	
51	
52	A
53	
54	C
55	
56	L
57	
58	Н
59	
	Р
60	•

the reliability of our findings. We conducted all statistical analyses using either R
version 4.1.2, GraphPad Prism 6 software, or MedCalc 20.1. The significance level was
set at p< 0.05.

- 149 **Patient and public involvement**
- 150 None.
- 151 **Results**
- 152 **Baseline population characteristics**

153 15754 individuals diagnosed with AKI after ICU admission within 48h were
154 selected for this analysis after excluding patients based on the exclusion criteria (Figure
155 1). In the whole cohort, the median age of patients was 68 years old, with 8998 (57.1%)
156 males and 6756 (42.9%) females. 8548 (54.3%) patients were diagnosed with AKI stage
157 1, 5695 (36.1%) with AKI stage 2, and 1511 (9.6%) with AKI stage 3.

In this study, patients were classified into non-dexmedetomidine (non-DEX, 158 n=12536) and dexmedetomidine (DEX, n=3218) groups. Compared with the non-DEX 159 group, the DEX group was younger, heavier weight, higher wbc, temperature, Spo2, 160 161 sofa score and SAPS II score, faster respiratory rate and heart rate, lower platelet, creatinine, bun, lactate, congestive heart failure and renal disease, more female, white 162 ethnicity, emergency admission, vasopressin use, MV, CRRT, chronic pulmonary, liver 163 disease, propofol use, midazolam use fentanyl use 164 AKI stage 1, sepsis and antibiotics use. After PSM, the characteristics of 3196 patients in both groups were 165 comparable (SMD< 0.1) (Table 1). 166



Table 1. Baseline characteristics for the two groups before and after matching.

1 E							
45 46 47	Characteristic	Before PSM			After PSM		
47 48		Non-DEX	DEX	SMD	Non- DEX	DEX	SMD
49 50		(n=12536)	(n=3218)		(n=3196)	(n=3196)	
51 52	Age (y)	69.00 [58.00, 79.00]	63.00 [52.00, 73.00]	0.377	64.00 [53.00, 73.00]	63.00 [52.00, 73.00]	0.018
53 54	Gender, male, n (%)	6903 (55.1)	2095 (65.1)	0.206	2088 (65.3)	2077 (65.0)	0.007
55 56	Laboratory measurements						
57 58	Hemoglobin (g/dL)	10.50 [8.90, 12.00]	10.40 [8.90, 12.20]	0.012	10.40 [8.80, 12.10]	10.40 [8.90, 12.20]	0.004
59 60	Platelet (×10 ⁹ /L)	188.00 [137.00, 247.54]	174.00 [130.37, 229.46]	0.146	175.35 [127.48, 229.91]	173.90 [130.31, 229.50]	0.009

1 2							
3 4	WBC (×10 ⁹)	11.10 [8.30, 14.70]	11.86 [9.00, 15.50]	0.075	11.80 [8.70, 15.55]	11.86 [9.00, 15.48]	0.013
5 6	Creatinine (mg/dL)	1.10 [0.80, 1.60]	1.00 [0.80, 1.50]	0.108	1.00 [0.70, 1.50]	1.00 [0.80, 1.50]	0.001
7 8	BUN (mg/dL)	21.00 [15.00, 35.00]	19.00 [14.00, 28.06]	0.177	19.00 [13.00, 29.00]	19.00 [14.00, 28.06]	0.006
9 10	Lactate (mmol/L)	2.02 [1.41, 2.30]	1.83 [1.37, 2.43]	0.051	1.88 [1.38, 2.43]	1.83 [1.37, 2.43]	0.019
11 12	Vital signs						
13 14	Weight (kg)	80.80 [68.00, 96.00]	86.00 [71.60, 101.00]	0.095	85.00 [71.00, 100.00]	86.00 [71.60, 101.00]	0.041
15 16	Temperature (°C)	36.83 [36.57, 37.09]	36.91 [36.71, 37.30]	0.289	36.88 [36.66, 37.29]	36.91 [36.71, 37.29]	0.033
17 18	Respiratory rate (bpm)	18.83 [16.68, 21.64]	19.09 [16.96, 21.89]	0.069	18.97 [16.88, 21.72]	19.08 [16.95, 21.87]	0.031
19 20	Heart rate (bpm)	84.03 [74.35, 96.08]	84.47 [76.30, 96.94]	0.074	84.74 [75.56, 97.25]	84.41 [76.28, 96.85]	0.007
21 22	MAP (mmHg)	75.49 [69.80, 82.95]	75.66 [70.74, 81.85]	0.004	75.74 [70.47, 82.39]	75.64 [70.73, 81.84]	0.021
23 24	Spo2 (%)	97.25 [95.77, 98.59]	97.60 [96.20, 98.77]	0.131	97.72 [96.25, 98.93]	97.61 [96.20, 98.77]	0.031
25 26	Ethnicity, white, n (%)	8516 (67.9)	2039 (63.4)	0.096	2048 (64.1)	2030 (63.5)	0.012
20 27 28	Admission type, emergency, n	6720 (53.6)	1369 (42.5)	0.223	1393 (43.6)	1365 (42.7)	0.018
29	(%)						
30 31	Need of support, n (%)						
32 33	Vasopressors	1221 (9.7)	600 (18.6)	0.257	554 (17.3)	596 (18.6)	0.034
34 35 36 37	MV	2977 (23.7)	1069 (33.2)	0.211	1122 (35.1)	1068 (33.4)	0.036
	CRRT	768 (6.1)	367 (11.4)	0.187	333 (10.4)	363 (11.4)	0.030
38 39	Comorbidities at ICU						
40 41	admission, n (%)						
42 43	Congestive heart failure	4314 (34.4)	951 (29.6)	0.104	924 (28.9)	948 (29.7)	0.017
44 45	Cerebrovascular disease	2139 (17.1)	504 (15.7)	0.038	506 (15.8)	502 (15.7)	0.003
46 47	Chronic pulmonary	3331 (26.6)	914 (28.4)	0.041	901 (28.2)	907 (28.4)	0.004
48 49	Renal disease	3143 (25.1)	602 (18.7)	0.154	610 (19.1)	598 (18.7)	0.010
50 51	Liver disease	1701 (13.6)	488 (15.2)	0.046	504 (15.8)	487 (15.2)	0.015
52 53	Diabetes	4023 (32.1)	984 (30.6)	0.033	971 (30.4)	979 (30.6)	0.005
54 55	Severity of illness						
56 57	SOFA score	6.00 [3.00, 8.00]	8.00 [5.00, 11.00]	0.451	7.00 [5.00, 11.00]	8.00 [5.00, 11.00]	0.027
58 59 60	SAPS II score	39.00 [31.00, 48.00]	40.00 [32.00, 50.00]	0.089	40.00 [31.00, 50.00]	40.00 [32.00, 50.00]	0.003

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1								
2 3 4	Sedative-analges	sic						
5 6	medications, n (9	%)						
7 8	Propofol		6289 (50.2)	2924 (90.9)	0.997	2902 (90.8)	2902 (90.8)	< 0.001
9 10	Midazolam		3049 (24.3)	1262 (39.2)	0.324	1234 (38.6)	1246 (39.0)	0.008
11 12	Fentanyl		6018 (48.0)	2586 (80.4)	0.717	2601 (81.4)	2564 (80.2)	0.029
13 14	AKI stage, n (%)				0.063			0.034
15 16	1		6722 (53.6)	1826 (56.7)		1812 (56.7)	1810 (56.6)	
17 18	2		4593 (36.6)	1102 (34.2)		1123 (35.1)	1096 (34.3)	
19 20	3		1221 (9.7)	290 (9.0)		261 (8.2)	290 (9.1)	
21 22	Sepsis, n (%)		8011 (63.9)	2590 (80.5)	0.377	2550 (79.8)	2568 (80.4)	0.014
23 24	Antibiotic, n (%))	9852 (78.6)	3016 (93.7)	0.449	2991 (93.6)	2994 (93.7)	0.004
25 26	Glucocorticoid, n (%)		2186 (17.4)	544 (16.9)	0.014	530 (16.6)	543 (17.0)	0.011
27 28	Outcome, n (%)							
29 30	In-hospital mortal	lity	1930 (15.4)	432 (13.4)		563 (17.6)	431 (13.5)	
31 32	180-day mortality	/	3725 (29.7)	704 (21.9)	0.	868 (27.2)	703 (22.0)	
33	168		pressed as M±SD/med					
34 35	169	_		DEX, Dexmedetomidine; SAP				
35 36	170		· · · ·	The Sequential Organ Failure	Assessment; MV,	Mechanical ventilation	on; CRRT, continuous renal	
37 38	171 172	replacement t	therapy; AKI, Acute ki	dney disease.				
39 40	173	Primary	y Outcome					
41 42	174	·		lity: We found that	DEX use de	creased in-hos	nital mortality risk	
43 44	175		1	lly ill patients with				
45		-	-					
46 47	176		C	over, Cox proportio		C X	,	
48 49	177				-		sion (OR: 0.64, 95%	
50 51	178			mentary table 2) we			C	
52 53	179	C		in in-hospital morta	2	C C		
54 55	180		-	stage 1 (15.6% vs.	· 1		(18.5% vs. 14.7%,	
56	181	p= 0.017	7) but not stage	e 3 (27.6% vs. 26.6	%, p= 0.848) (Fig.3).		

57 58 182 Second Outcome

59

60

183 180-day mortality: DEX use also reduced 180-day mortality risk by 23% among

critically ill patients with AKI (HR: 0.77, 95% CI: 0.69-0.85) during PSM modeling. Moreover, Cox proportional hazards regression (HR: 0.68, 95% CI: 0.63-0.74) (Fig.2, Supplementary table 3) and binary logistic regression (OR: 0.64, 95% CI: 0.57-0.71) (Supplementary table 4) were consistent with the trend of PSM modeling. A significant decrease in 180-day mortality was observed among critically ill patients receiving DEX at AKI stage 1 (24.7% vs. 18.2%, p< 0.001), stage 2 (28.3% vs. 24.0%, p= 0.023) but not stage 3 (39.1% vs. 38.3%, p= 0.861) (Fig.3).

191 We conducted a check on the goodness of fit of the model and found that p< 192 0.05, indicates a good fit of the model. We also investigated the in-hospital and 180-193 day survival in critical patients with AKI. The DEX group had significantly higher 194 freedom from death at in-hospital (86.5 vs. 82.4%, p < 0.001) and 180-day (78.0 vs. 195 72.8%, p < 0.001) than the non-DEX group, respectively (Fig.4).

Overall, the use of DEX had a significant beneficial effect on the in-hospitalmortality and 180-day mortality of AKI in critically ill patients.

198 Subgroup analysis

 Subgroup analysis indicated that DEX use reduced in-hospital mortality of critically ill patients with AKI (Supplementary Figure 1). There were no interactions between age, gender, sepsis, AKI stage, and DEX use, suggesting that these results were comparable for all populations.

203 Discussion

The present study showed that DEX use in severely ill AKI patients was linked with lower risk-adjusted in-hospital mortality and 180-day mortality. Consistent results were observed in different models. During subgroup analysis, after stratification according to age, gender, AKI stage, and sepsis, a strong correlation was still observed. Overall, we provide preliminary evidence that DEX has a beneficial effect on the prognosis of AKI in critically ill patients, providing the foothold to improve the outcomes of this patient population.

Overwhelming literature substantiates that DEX can alleviate AKI caused by
several factors. Ruegg et al. in a review summarized the role of dexmedetomidine in
preventing acute kidney injury in intensive care.[26] Wang et al. previously uncovered

Page 11 of 31

BMJ Open

that DEX could ameliorate AKI in mice with sepsis by partially inhibiting oxidative stress and apoptosis by modulating the p75NTR/p38MAPK/JNK signaling pathways.[27] Zhao et al. further substantiated that DEX protected against lipopolysaccharide-induced AKI by promoting autophagy mediated by PI3K/AKI/mTOR pathway inhibition.[28] A meta-analysis by Loomba et al. demonstrated that DEX could confer postoperative renal protective effects with lower NGAL levels and increased creatine clearance in patients who received DEX. These effects correlated with reduced ICU length of stay and risk of AKI and mortality.[29] Shan et al. found that DEX could minimize AKI incidence in Stanford type B aortic dissection (TBAD) patients after endovascular aortic repair (EVAR).[30] A single-center RCT of 108 patients[31] showed that prior administration of DEX within 24 hours after induction of anesthesia could reduce the incidence of AKI after aortic surgery under cardiopulmonary bypass. An RCT by Tang et al.[32] showed that DEX pretreatment attenuated AKI in patients. Animal studies further indicated that DEX could reduce cellular injury, improve renal function, and mitigate apoptosis in renal cells. Furthermore, Liu et al. revealed that DEX infusion in ICU patients with septic shock was linked to decreased AKI incidence and reduced ICU stay and CRRT performance. It is highly conceivable that the mechanism is related to anti-inflammatory effects and immunomodulation.[33]

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Inflammation is key to AKI pathogenesis, progression, and prognosis. An increasing body of evidence suggests that DEX confers renoprotective effects and may be involved in the regulation of inflammation.[34-36] A meta-analysis by Ma et al.[37] that included 4842 patients showed that DEX decreased pro-inflammatory like cytokines interleukin-6. C-reactive, tumor necrosis factor- α , and increased antiinflammatory cytokines like IL-10 in surgical patients. A sub-analysis of a multicenter RCT by Ohta et al.[38] suggested that sedation using DEX reduced inflammation in patients with sepsis requiring mechanical ventilation. Animal studies have shown that DEX may have a protective effect on cisplatin-induced AKI, and its potential mechanism may be related to the regulation of apoptosis and inflammatory response.[39] In addition, DEX can ameliorate microcirculation disorders by

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

decreasing norepinephrine levels in the blood and increasing urine output and renal blood flow.[40] Since our study did not collect inflammatory indicators, the hypothesis that DEX may attenuate excessive inflammation could not be confirmed, emphasizing the need for future studies. Emerging evidence substantiates the benefits of DEX in AKI, but the prognosis and follow-up of AKI in critically ill patients have been largely understudied. In the present study, we consistently found that the in-hospital mortality of AKI patients in the DEX group was significantly lower than in the non-DEX group. At the same time, we found that the 180-day mortality of AKI patients was consistent with the in-hospital mortality, suggesting that DEX use is associated with survival benefits in this particular patient population. Our research provides a theoretical basis for clinicians to use DEX to manage critically ill patients with AKI. In our research results, we also found that propofol reduced the risk of in-hospital mortality and 180day mortality, and we speculate that this may be due to the renal protective effect of propofol,[41-42] this finding may also be due to the fact that propofol may be give more often to patients who are hemodynamically more stable and therefore more like to survive. The commonly used sedative drugs in ICU are propofol, dexmedetomidine, and midazolam, which can be used alone or in combination. There was no statistically significant difference in the use of propofol between the two groups after PSM, and we also adjusted for propofol as a confounding factor in the logistic regression analysis, and the interference of propofol on death outcomes was excluded.

Our subgroup analysis showed that DEX was effective in sepsis-associated-AKI (SA-AKI) patients, consistent with the literature.²¹ Consistently, Hu et al. analyzed 2192 patients with SA-AKI and found that DEX use was related to decreased in-hospital mortality and improved renal function recovery of SA-AKI in critically ill patients. Unlike Hu's study is that our study included all types of AKI populations in the ICU. Our results showed that DEX use reduced in-hospital mortality of AKI in critically ill patients. Follow-up analysis showed that DEX use reduced the 180-day mortality of patients. Our findings suggest DEX is effective against sepsis-associated AKI and for AKI patients in general and improves the long-term prognosis. The role of DEX on more types of AKI subgroups warrants further exploration in severely ill

Page 13 of 31

BMJ Open

subjects. Our study found that using DEX in critically ill patients with AKI can reduce in-hospital mortality and 180-day mortality. In the figure 3 we conducted a chi-square test from group comparisons and the impact of confounding factors was not included. In the subgroup analysis in the supplementary figures we used binary logistic regression analysis and include the influence of confounding factors. After adjusting for confounding factors, DEX can reduce all three stages of AKI in in-hospital mortality. Shehabi et al.[43] found that early use of DEX sedation can reduce the 90-day mortality in elderly patients with critically ill mechanical ventilation in the SPICE III trial, whether the patient has surgery or not. On the contrary, a higher likelihood of an increase in 90-day mortality was observed in younger patients of non-surgical status. However, it has not been thoroughly researched for the use of DEX sedation in critically ill patients with AKI, and this study can serve as a supplement to such patients in the SPICE III trial.

Our research has several limitations. First, data acquired from this database was adopted to maximize generalizability and power. Accordingly, there was no formal calculation of sample size in this study. Although the sample size of the subgroup was comparatively larger compared to previous studies, it may also increase the risk of false positive results during multiple subgroup analyses. Second, our study's retrospective nature may have limited our findings' accuracy, and there could be other unknown potentially confounding factors that we were unable to control for. Third, we adjusted for many confounding factors, and PSM was conducted. Moreover, data analyzed in this study were acquired from a single-center observation database, emphasizing the need for a multicenter RCT to increase the robustness of our findings. Forth, due to the lack of admission diagnosis recorded in the MIMIC database, it is difficult for us to accurately identify the etiology of AKI in each patient. Therefore, the AKI patients defined in this study are actually unselected AKI. Although it is difficult to determine the exact cause of AKI and the reason why patients are admitted to the ICU, we have made necessary adjustments for other confounding factors that affect patient mortality. Our conclusion is stable and reliable, and may only apply to unselected AKI in critically ill patients. Fifth, this study did not consider the dosage and duration of DEX use, and Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

further attention is needed in future studies. Sixth, in this study we did not consider changes in exposure or covariates over time. Due to the large number and heterogeneity of patients, it is difficult to quantify or qualitatively measure the changes in exposure or covariates of all patients over time. We focus on the measurement indicators of patients at admission, and only by analyzing this time point can we have significant value in promoting and applying our conclusions in clinical practice.

310 Conclusion

This retrospective cohort study showed that dexmedetomidine administration is associated with reduced risk-adjusted in-hospital and 180-day mortality in critically ill patients with AKI. However, further RCTs are needed to develop the robustness of our findings.

316 Acknowledgements We would like to thank the participants, patient advisers,

- 317 developers and investigators associated with the Medical Information Mart for
- 318 Intensive Care (MIMIC)-IV database.
- **Contributors** WW and JL designed the study. YJ and PZ conducted data collection.
- 320 PG and HW conducted data analysis. WW wrote the manuscript. WW and JL
- 321 analyzed and interpreted the result. All authors reviewed this manuscript.
- **Funding** This study was supported by The National Natural Science Fundation of
- 323 China (grant number: 81960669) and The National High Level Hospital Clinical
- 324 Research Funding (grant number: 2022-GSP-GG-22).
- **Competing interests** None declared.
- 326 Patient and public involvement Patients and/or the public were not involved in the327 design, or conduct, or reporting, or dissemination plans of this research.
- **Data availability statement** Data are available upon reasonable request.
- **Patient consent for publication** Not required.
- **Ethics approval** Considering that this study was based on the analysis of an
- anonymous third-party public database with prior approval from the Institutional
- 332 Review Board, no ethical review was required.

BMJ Open

1 2 3		
4	334	Reference:
5 6 7 8 9	335	[1] Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global
	336	concern. Lancet 2013; 382: 170-179. doi:10.1016/S0140-6736(13)60647-9
9 10	337	[2] Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in
11 12	338	critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41:
13 14	339	1411-1423. doi:10.1007/s00134-015-3934-7
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	340	[3] Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk
	341	stratification, and outcomes. Kidney Int 2012; 81: 819-25. doi:10.1038/ki.2011.339
	342	[4] Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core
	343	curriculum 2018. Am J Kidney Dis 2018; 72: 136–48.doi:10.1053/j.ajkd.2017.11.021
	344	[5] Altshuler J, Spoelhof B. Pain, agitation, delirium, and neuromuscular blockade: a
	345	review of basic pharmacology, assessment, and monitoring. Crit Care Nurs Q
	346	2013;36: 356–69.doi:10.1097/CNQ.0b013e3182a10dbf
	347	[6] Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J
	348	Anaesthesiol 2011;28: 3-6.doi:10.1097/EJA.0b013e32833e266d
	349	[7] Møller MH, Alhazzani W, Lewis K, et al. Use of dexmedetomidine for sedation in
	350	mechanically ventilated adult ICU patients: a rapid practice guideline. Intensive Care
	351	Med 2022; 48(7): 801-810. doi:10.1007/s00134-022-06660-x
	352	[8] Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more
	353	than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive
42 43	354	Care Med 2004; 30: 2188-2196.doi:10.1007/s00134-004-2417-z
44 45	355	[9] Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress,
46 47	356	inflammation, and immune function: systematic review and meta-analysis. Br J
48 49	357	Anaesth 2019; 123: 777-94.doi:10.1016/j.bja.2019.07.027
50 51	358	[10] Shan XS, Dai HR, Zhao D, et al. Dexmedetomidine reduces acute kidney injury
52 53	359	after endovascular aortic repair of Stanford type B aortic dissection: A randomized,
54 55	360	double-blind, placebo-controlled pilot study. J Clin Anesth 2021; 75: 110498.
56 57	361	doi:10.1016/j.jclinane.2021.110498
58 59	362	[11] Zhai M, Kang F, Han M, et al. The effect of dexmedetomidine on renal function
60	363	in patients undergoing cardiac valve replacement under cardiopulmonary bypass: A

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

364	double-blind randomized controlled trial. J Clin Anesth 2017; 40:33-38.
365	doi:10.1016/j.jclinane.2017.03.053
366	[12] Zhao Y, Feng X, Li B, et al. Dexmedetomidine Protects Against
367	Lipopolysaccharide-Induced Acute Kidney Injury by Enhancing Autophagy Through
368	Inhibition of the PI3K/AKT/mTOR Pathway. Front Pharmacol 2020; 11: 128.
369	doi:10.3389/fphar.2020.00128
370	[13] Loomba RS, Villarreal EG, Dhargalkar J, et al. The effect of dexmedetomidine
371	on renal function after surgery: A systematic review and meta-analysis. J Clin Pharm
372	Ther 2022; 47(3): 287-297. doi:10.1111/jcpt.13527
373	[14] Johnson A, Bulgarelli L, Pollard T, et al. MIMIC-IV (version 2.0). PhysioNet
374	2022. Available from: https://doi.org/10.13026/7vcr-e114.
375	[15] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
376	Observational Studies in Epidemiology (STROBE) Statement: guidelines for
377	reporting observational studies. Int J Surg 2014; 12: 1495-
378	1499.doi:10.1016/j.ijsu.2014.07.013
379	[16] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron
380	Clin Pract 2012; 120: c179-84. doi:10.1159/000339789
381	[17] De Rosa S, Samoni S, Ronco C. Creatinine-based definitions: from baseline
382	creatinine to serum creatinine adjustment in intensive care. Crit Care 2016; 20: 69.
000	

- doi:10.1186/s13054-016-1218-4
- [18]Vincent J-L, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess
- the incidence of organ dysfunction/failure in intensive care units: results of a
- multicenter, prospective study. Crit Care Med 1998; 26: 1793-800.
- doi:10.1097/00003246-199811000-00016
- [19] Sánchez-Díaz JS, Escarraman-Martínez D, Guerrero-Gutiérrez MA, et al.
- Simplified acute physiology score II and Mannheim peritonitis index are associated
- with in-hospital mortality in patients with abdominal sepsis admitted to ICU.
- Simplified acute physiology score II y Mannheim peritonitis index se asocian a
- mortalidad intrahospitalaria en pacientes con sepsis abdominal ingresados a la UCI.
- Cir Cir 2022; 90: 81-91. doi:10.24875/CIRU.22000219

BMJ Open

1 2		
3 4	394	[20] Tao L, Zhou S, Chang P, et al. Effects of ondansetron use on outcomes of acute
5 6	395	kidney injury in critically ill patients: An analysis based on the MIMIC-IV database. J
7 8 9 10	396	Crit Care 2021; 66: 117-122. doi:10.1016/j.jcrc.2021.07.015
	397	[21] Hu H, An S, Sha T, et al. Association between dexmedetomidine administration
11 12	398	and outcomes in critically ill patients with sepsis-associated acute kidney injury. J
13 14	399	Clin Anesth 2022; 83: 110960. doi:10.1016/j.jclinane.2022.110960
15 16	400	[22] Chen S, Li S, Kuang C, et al. Aspirin reduces the mortality risk of sepsis-
17 18	401	associated acute kidney injury: an observational study using the MIMIC IV database.
19 20	402	Front Pharmacol 2023; 14: 1186384. doi:10.3389/fphar.2023.1186384
20 21 22	403	[23] Singer M, Deutschman CS, Seymour CW, et al. The Third International
23	404	Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (8):
24 25	405	801-810. doi:10.1001/jama.2016.0287
26 27	406	[24] Zhang Z, Xu X, Ni H, et al. Urine output on ICU entry is associated with hospital
28 29 30 31	407	mortality in unselected critically ill patients. J Nephrol 2014;27 (1):65-71.
	408	doi:10.1007/s40620-013-0024-1
32 33	409	[25] Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the
34 35	410	assessment of measured covariate balance to test causal associations in psychological
36 37 38 39 40 41	411	research. Psychol Methods 2010; 15 (3): 234-249. doi:10.1037/a0019623
	412	[26] Gion Ruegg, Nora Luethi, Luca Cioccari. The Role of Dexmedetomidine for the
	413	Prevention of Acute Kidney Injury in Critical Care. EMJ Nephrol 2021; 9 [1]: 97-106.
42 43	414	https://doi.org/10.33590/emjnephrol/21-00087
44 45	415	[27] Wang Z, Wu J, Hu Z, et al. Dexmedetomidine Alleviates Lipopolysaccharide-
46 47	416	Induced Acute Kidney Injury by Inhibiting p75NTR-Mediated Oxidative Stress and
48 49	417	Apoptosis. Oxid Med Cell Longev 2020; 2020: 5454210. doi:10.1155/2020/5454210
50 51	418	[28] Zhao Y, Feng X, Li B, et al. Dexmedetomidine Protects Against
52 53	419	Lipopolysaccharide-Induced Acute Kidney Injury by Enhancing Autophagy Through
54 55	420	Inhibition of the PI3K/AKT/mTOR Pathway. Front Pharmacol 2020; 11: 128.
56 57	421	doi:10.3389/fphar.2020.00128
58 59	422	[29] Loomba RS, Villarreal EG, Dhargalkar J, et al. The effect of dexmedetomidine
59 60	423	on renal function after surgery: A systematic review and meta-analysis. J Clin Pharm

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2	
3	
4	
5	
6	
6 7	
8	
9	
10	
11	
12	
13	
14	
15	
16 17	
17	
18	
19	
20	
21	
21 22	
23	
24	
25	
25	
26 27	
27	
28	
29 30	
30	
31	
32	
33	
34	
35	
36 37	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
46 47	
48	
49 50	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1

- 424 Ther 2022; 47: 287-297. doi:10.1111/jcpt.13527
- 425 [30] Shan XS, Dai HR, Zhao D, et al. Dexmedetomidine reduces acute kidney injury
 - 426 after endovascular aortic repair of Stanford type B aortic dissection: A randomized,
- 427 double-blind, placebo-controlled pilot study. J Clin Anesth 2021; 75: 110498.
- 428 doi:10.1016/j.jclinane.2021.110498
- 429 [31] Soh S, Shim JK, Song JW, et al. Effect of dexmedetomidine on acute kidney
- 430 injury after aortic surgery: a single-centre, placebo-controlled, randomised controlled
- 431 trial. Br J Anaesth 2020; S0007-0912 (20) 30001-5. doi:10.1016/j.bja.2019.12.036
- 432 [32] Tang C, Hu Y, Gao J, et al. Dexmedetomidine pretreatment attenuates
- 433 myocardial ischemia reperfusion induced acute kidney injury and endoplasmic
- 434 reticulum stress in human and rat. Life Sci 2020; 257: 118004.
- 435 doi:10.1016/j.lfs.2020.118004
- 436 [33] Liu J, Shi K, Hong J, et al. Dexmedetomidine protects against acute kidney
- 437 injury in patients with septic shock. Ann Palliat Med 2020; 9: 224-230.
- 438 doi:10.21037/apm.2020.02.08
- 439 [34] Zhang J, Bi J, Ren Y, et al. Involvement of GPX4 in irisin's protection against
- 440 ischemia reperfusion-induced acute kidney injury. J Cell Physiol 2021; 236: 931-945.
- 441 doi:10.1002/jcp.29903
- 442 [35] Zhao M, Wang Y, Li L, et al. Mitochondrial ROS promote mitochondrial
- 443 dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-
- 444 mediated mtDNA maintenance. Theranostics 2021; 11: 1845-1863.
- 445 doi:10.7150/thno.50905
- 446 [36] Hasegawa S, Inoue T, Nakamura Y, et al. Activation of Sympathetic Signaling in
- 447 Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-
- 448 Reperfusion Injury. J Am Soc Nephrol 2021; 32, 1599–1615.
- 449 doi:10.1681/ASN.2020121723
- 450 [37] Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress,
- 451 inflammation, and immune function: systematic review and meta-analysis. Br J
- 452 Anaesth 2019; 123: 777-794. doi:10.1016/j.bja.2019.07.027
- 453 [38] Ohta Y, Miyamoto K, Kawazoe Y, et al. Effect of dexmedetomidine on

BMJ Open

2		
3 4	454	inflammation in patients with sepsis requiring mechanical ventilation: a sub-analysis
5 6	455	of a multicenter randomized clinical trial. Crit Care 2020; 24: 493.
7 8	456	doi:10.1186/s13054-020-03207-8
9 10	457	[39] Liang H, Liu HZ, Wang HB, et al. Dexmedetomidine protects against cisplatin-
11 12	458	induced acute kidney injury in mice through regulating apoptosis and inflammation.
13 14	459	Inflamm Res 2017; 66: 399-411. doi:10.1007/s00011-017-1023-9
15 16	460	[40] Ebert Thomas J, Hall Judith E, Barney Jill A, et al. The effects of increasing
17 18	461	plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93:
19 20	462	382–94. doi:10.1097/00000542-200008000-00016
21 22	463	[41] Song Y, Paik HC, Kim N, et al. Effect of Propofol versus Sevoflurane Anesthesia
23 24	464	on Acute Kidney Injury after Lung Transplantation Surgery: A Prospective
24 25 26	465	Randomized Controlled Trial. J Clin Med 2022; 11 (22): 6862.
20 27 28	466	[42] Leite TT, Macedo E, Martins Ida S, et al. Renal Outcomes in Critically Ill
29	467	Patients Receiving Propofol or Midazolam. Clin J Am Soc Nephrol 2015; 10 (11):
30 31	468	1937-1945. doi:10.2215/CJN.02330315
32 33	469	[43] Shehabi Y, Serpa Neto A, Howe BD, et al. Early sedation with dexmedetomidine
34 35	470	in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE
36 37	471	III randomised controlled trial. Intensive Care Med 2021; 47 (4): 455-466.
38 39	472	doi:10.1007/s00134-021-06356-8
40 41	473	
42 43	474	
44 45	475	
46 47	476	Figure Legends:
48	477	Fig.1. Flowchart of patients selection for the study. MIMIC-IV: Medical Information Mart for
49 50	478	Intensive Care Database IV; ICU: intensive care unit.
51 52	479	Fig.2. Association between in-hospital mortality, 180-day mortality and dexmedetomidine use of
53 54	480	AKI patients evaluated by the Cox model. HR, hazard ratio; CI: confidence interval; Unadjusted:
55 56	481	without adjustment; Multivarable adjusted: adjusted for all the baseline variables shown in Table 1.
57 58	482	PSM: propensity score matching.
59 60	483	Fig.3. In-hospital mortality and 180-day mortality of AKI in critically ill patients between the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2
3
4
5
6 7
8
9
10
11
13
14
15
16
17
18
19
20
20 21
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
~~
40
41
42
43
44
45
46
47
48
40 49
50
51
52
53
54
55
56
57


58 59 60


1

484	dexmedetomidine and	non-dexmedetomidine g	group in different AKI stage.
-----	---------------------	-----------------------	-------------------------------

- Fig.4. Freedom from death at in-hospital and 180-day in critically ill patients with AKI between thetwo groups.
- 487 Supplementary figure 1. Subgroup analysis of the association between dexmedetomidine use and
- 488 in-hospital mortality. For beer teries only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml









Fig.2. Association between in-hospital mortality, 180-day mortality and dexmedetomidine use of AKI patients evaluated by the Cox model. HR, hazard ratio; CI: confidence interval; Unadjusted: without adjustment; Multivarable adjusted: adjusted for all the baseline variables shown in Table 1. PSM: propensity score matching.

338x190mm (96 x 96 DPI)






Fig.4. Freedom from death at in-hospital and 180-day in critically ill patients with AKI between the two groups.

338x190mm (96 x 96 DPI)

Supplementary table 1.

Cox logistic regression analysis of in-hospital mortality (before PSM)

	Univariable		Multivariable	Multivariable	
Variables	HR (95%CI)	<i>P</i> value	HR (95%CI)	<i>P</i> value	
Need of support					
Vasopressors	2.636 (2.415, 2.877)	<0.001	1.394 (1.251, 1.553)	<0.001	
MV	4.108 (3.782, 4.462)	<0.001	4.090 (3.710, 4.509)	<0.001	
CRRT	1.863 (1.680, 2.065)	<0.001	0.845 (0.750, 0.952)	0.006	
Comorbidities at ICU admission					
Congestive heart failure	1.151 (1.058, 1.251)	0.001	1.229 (1.125, 1.342)	<0.001	
Cerebrovascular disease	1.437 (1.307, 1.581)	<0.001	1.547 [1.403, 1.705]	<0.001	
Chronic pulmonary	1.056 (0.965, 1.155)	0.237			
Renal disease	1.101 (1.005, 1.206)	0.040	1.025 [0.928, 1.132]	0.629	
Liver disease	1.651 (1.505, 1.812)	<0.001	1.120 (1.009, 1.244)	0.033	
Diabetes	0.901 (0.825, 0.984)	<0.001	0.818 [0.746, 0.898]	<0.001	
Severity of illness					
SOFA score	1.115 (1.105, 1.125)	<0.001	1.007 [0.993, 1.021]	0.350	
SAPS II score	1.033 (1.031, 1.036)	<0.001	1.018 (1.015, 1.021)	<0.001	
Sedative-analgesic medications					
Propofol	0.788 (0.725, 0857)	<0.001	0.465 (0.421, 0.513)	<0.001	
Midazolam	1.680 (1.547, 1.823)	<0.001	0.838 (0.758, 0.928)	0.001	
Fentanyl	1.724 (1.568, 1.895)	<0.001	1.309 (1.154, 1.486)	<0.001	
AKI stage					
AKI stage 1	Ref		Ref		
AKI stage 2	1.142 (1.071, 1.217)	<0.001	1.044 (0.955, 1.142)	0.342	
AKI stage 3	1.800 (1.646, 1.969)	<0.001	1.048 (0.928, 1.183)	0.453	
Lactate (mmol/L)	1.314 (1.292, 1.337)	<0.001	1.224 (1.199, 1.250)	<0.001	
Sepsis	1.871 (1.670, 2.096)	<0.001	1.574 (1.304, 1.901)	<0.001	
Antibiotic	1.366 (1.191, 1.562)	<0.001	0.665 (0.533, 0.831)	<0.001	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Glucocorticoid	0.719 (0.645, 0.801)	<0.001	0.709 (0.635, 0.791)	<0.001
DEX	0.585 (0.526, 0.650)	<0.001	0.610 (0.546, 0.680)	<0.001

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Supplementary table 2.

Binary logistic regression analysis of in-hospital mortality (before PSM)

	Univariable		Multivariable	
Variables	OR (95%CI)	<i>P</i> value	OR (95%CI)	<i>P</i> value
Need of support	0			
Vasopressors	5.730 (5.151, 6.375)	< 0.001	2.040 (1.766, 2.357)	< 0.001
MV	6.194 (5.645, 6.796)	<0.001	5.022 (4.468, 5.644)	<0.001
CRRT	4.960 (4.367, 5.633)	<0.001	1.320 (1.106, 1.575)	0.002
Comorbidities at ICU admission				
Congestive heart failure	1.186 (1.083, 1.299)	<0.001	1.294 (1.156, 1.448)	<0.001
Cerebrovascular disease	1.668 (1.500, 1.854)	<0.001	2.302 (2.029, 2.612)	< 0.001
Chronic pulmonary	1.069 (0.969, 1.178)	0.182		
Renal disease	1.206 (1.092, 1.333)	<0.001	1.010 (0.890, 1.146)	0.881
Liver disease	2.612 (2.350, 2.905)	<0.001	1.442 (1.253, 1.659)	< 0.001
Diabetes	0.886 (0.806, 0.975)	0.013	0.776 (0.691, 0.871)	< 0.001
Severity of illness				
SOFA score	1.222 (1.209, 1.236)	< 0.001	1.041 (1.021, 1.060)	<0.001
SAPS II score	1.054 (1.051, 1.057)	<0.001	1.029 (1.024, 1.033)	< 0.001
Sedative-analgesic medications				
Propofol	1.129 (1.032, 1.235)	0.008	0.462 (0.406, 0.526)	< 0.001
Midazolam	2.938 (2.685, 3.215)	<0.001	1.062 (0.935, 1.206)	0.353
Fentanyl	2.914 (2.638, 3.218)	<0.001	1.499 (1.296, 1.734)	< 0.001
AKI stage				
AKI stage 1	Ref		Ref	
AKI stage 2	1.149 (1.044, 1.265)	0.004	1.080 (0.967, 1.207)	0.174

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

AKI stage 3	2.139 (1.873, 2.442)	<0.001	1.105 (0.937, 1.305)	0.236
Lactate (mmol/L)	1.496 (1.449, 1.545)	<0.001	1.258 (1.212, 1.305)	< 0.001
Sepsis	3.145 (2.794, 3.539)	<0.001	1.878 (1.527, 2.310)	< 0.001
Antibiotic	2.246 (1.949, 2.587)	<0.001	0.723 (0.566, 0.923)	0.009
Glucocorticoid	0.961 (0.855, 1.080)	0.505		
DEX	0.852 (0.762, 0.953)	0.005	0.639 (0.556,0.734)	<0.001

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Supplementary table 3.

Cox logistic regression analysis of 180-day mortality (before PSM)

	Univariable		Multivariable
Variables	HR (95%CI)	P value	HR (95%CI) <i>P</i> value
Need of support		-	
Vasopressors	2.771 (2.579, 2.977)	< 0.001	1.454 (1.331, 1.588) <0.001
MV	2.626 (2.474, 2.788)	<0.001	2.565 (2.390, 2.752) <0.001
CRRT	2.554 (2.345, 2.783)	<0.001	0.995 (0.899, 1.101) 0.920
Comorbidities at ICU admission			
Congestive heart failure	1.318 (1.240, 1.400)	<0.001	1.194 (1.120, 1.273) <0.001
Cerebrovascular disease	1.423 (1.324, 1.530)	< 0.001	1.581 (1.469, 1.701) <0.001
Chronic pulmonary	1.129 (1.058, 1.204)	<0.001	1.104 (1.033, 1.180) 0.004
Renal disease	1.379 (1.293, 1.472)	<0.001	1.090 (1.017, 1.168) 0.015
Liver disease	1.881 (1.749, 2.022)	<0.001	1.249 (1.152, 1.355) <0.001
Diabetes	0.982 (0.922, 1.046)	0.580	
Severity of illness			
SOFA score	1.129 (1.121, 1.136)	<0.001	1.013 (1.001, 1.024) 0.029
SAPS II score	1.039 (1.037, 1.041)	<0.001	1.025 (1.023, 1.028) <0.001

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Sedative-analgesic medications				
Propofol	0.715 (0.674, 0.758)	< 0.001	0.448 (0.418, 0.482)	< 0.001
Midazolam	1.809 (1.703, 1.923)	<0.001	0.910 (0.841, 0.986)	0.021
Fentanyl	1.492 (1.404, 1.586)	<0.001	1.242 (1.140, 1.352)	< 0.001
AKI stage				
AKI stage 1	Ref		Ref	
AKI stage 2	1.142 (1.071, 1.217)	<0.001	1.076 (1.009, 1.148)	0.025
AKI stage 3	1.800 (1.646, 1.969)	<0.001	1.097 (0.999, 1.204)	0.051
Lactate (mmol/L)	1.250 (1.232, 1.268)	<0.001	1.155 (1.134, 1.176)	< 0.001
Sepsis	2.060 (1.915, 2.215)	<0.001	1.664 (1.478, 1.874)	< 0.001
Antibiotic	1.531 (1.404, 1.669)	<0.001	0.808 (0.703, 0.928)	0.003
Glucocorticoid	1.162 (1.079, 1.251)	<0.001	1.072 (0.994, 1.156)	0.071
DEX	0.693 (0.639, 0.751)	<0.001	0.683 (0.626,0.744)	< 0.001

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

N.C.N

Supplementary table 4.

Binary logistic regression analysis of 180-day mortality (before PSM)

	Univariable		Multivariable	
Variables	OR (95%CI)	P value	OR (95%CI)	<i>P</i> value
Need of support				
Vasopressors	3.346 (3,028, 3.697)	< 0.001	1.604 (1.407, 1.828)	< 0.001
MV	2.960 (2.744, 3.193)	< 0.001	3.059 (2.777, 3.371)	< 0.001
CRRT	3.273 (2.896, 3.699)	< 0.001	1.117 (0.954, 1.309)	0.170
Comorbidities at ICU admission	1			
Congestive heart failure	1.416 (1.318, 1.523)	< 0.001	1.284 (1.178, 1.401)	< 0.001
Cerebrovascular disease	1.504 (1.376, 1.643)	<0.001	1.926 (1.740, 2.131)	< 0.001

Chronic pulmonary	1.171 (1.084, 1.265)	<0.001	1.156 (1.057, 1.264)	0.002
Renal disease	1.511 (1.397, 1.635)	<0.001	1.114 (1.014, 1.225)	0.025
Liver disease	2.125 (1.936, 2.332)	<0.001	1.458 (1.298, 1.638)	< 0.001
Diabetes	0.993 (0.922, 1.070)	0.860		
Severity of illness				
SOFA score	1.156 (1.145, 1.166)	<0.001	1.012 (0.997, 1.028)	<0.001
SAPS II score	1.052 (1.049, 1.054)	<0.001	1.039 (1.035, 1.043)	<0.001
Sedative-analgesic medications				
Propofol	0.663 (0.618, 0.711)	<0.001	0.335 (0.302, 0.371)	<0.001
Midazolam	2.017 (1.871, 2.173)	<0.001	1.020 (0.918, 1.133)	0.709
Fentanyl	1.563 (1.456, 1.678)	<0.001	1.346 (1.206, 1.501)	<0.001
AKI stage				
AKI stage 1	Ref		Ref	
AKI stage 2	1.170 (1.085, 1.261)	<0.001	1.116 (1.026, 1.215)	0.011
AKI stage 3	2.014 (1.797, 2.256)	<0.001	1.151 (1.007, 1.314)	0.039
Lactate (mmol/L)	1.349 (1.310, 1.389)	<0.001	1.173 (1.135, 1.213)	< 0.001
Sepsis	2.293 (2.112, 2.489)	<0.001	1.790 (1.560, 2.053)	< 0.001
Antibiotic	1.630 (1.478, 1.797)	<0.001	0.827 (0.704, 0.971)	0.021
Glucocorticoid	1.236 (1.131, 1.352)	<0.001	1.244 (1.124, 1.376)	< 0.001
DEX	0.662 (0.604, 0.726)	<0.001	0.636 (0.569,0.711)	< 0.001

PSM, Propensity Score Matching; DEX, Dexmedetomidine; SAPS, Simplified Acute Physiology Score; SOFA, The Sequential Organ Failure Assessment; MV, Mechanical ventilation; CRRT, continuous renal replacement therapy; AKI, Acute kidney disease.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Supplementary figure 1

Subgroup	No. of Patients		OR (95% CI)	P for interaction				
Age				0.6				
≥60	10953	⊢■→	0.69 (0.60-0.78)					
<60	4801	⊨-∎1	0.445 (0.36-0.55)					
Gender				0.57				
Female	6756	⊢ ∎1	0.61 (0.53-0.71)					
Male	8998	⊢_∎ 1	0.70 (0.59-0.83)					
ΑΚΙ				0.69				
Stage 1	8548	⊢ ∎1	0.63 (0.53-0.74)					
Stage 2	5695	⊢ _∎4	0.70 (0.58-0.85)					
Stage 3	1511	⊢	0.62 (0.47-0.81)					
Sepsis				0.35				
Yes	10601	⊢■→	0.66 (0.59-0.74)					
No	5153	⊢−−	0.51 (0.34-0.77)					
			1					
	C	0.325 0.50.60.70.80.9 [·]	1					
<dexmedetomidine better="" betterno="" dexmedetomidine=""></dexmedetomidine>								

Supplementary figure 1. Subgroup analysis of the association between dexmedetomidine use and in-hospital mortality.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

STROBE Statement-Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Pag No
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the	1
		abstract	2
		(<i>b</i>) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction		done and what was found	
Background/rationale	2	Explain the scientific background and rationale for the investigation being	3
Buenground, futionale	-	reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of	4
		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	4
		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	5
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	4
		effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	5
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	-
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	5
		describe which groupings were chosen and why	4
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	4
		(b) Describe any methods used to examine subgroups and interactions	4
		(c) Explain how missing data were addressed	5
		(d) If applicable, explain how loss to follow-up was addressed	
		(<u>e</u>) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	6
1		eligible, examined for eligibility, confirmed eligible, included in the study,	
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	Yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	6
		and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	6

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

1	-
1	
2	
3	
4	
5	
6	
7	
8	_
9	
10	
11	-
12	
13	-
14	-
14	
16 17	
17	
18	-
19	
20	-
21	-
22	
23	
24	-
25	
26	*
27	
28	ľ
29	1
30	P
31	а
32	ł
33	
34	а
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	

59 60

Main results		(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6
		(b) Report category boundaries when continuous variables were categorized(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	6
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6
Discussion			
Key results	18	Summarise key results with reference to study objectives	7
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9
Generalisability	21	Discuss the generalisability (external validity) of the study results	8.9
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.